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USE OF VITELLINE PROTEIN B AS A
MICROENCAPSULATING ADDITIVE
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a divisional of U.S. Ser. No. 11/015,
734, filed on Dec. 17, 2004, entitled "Use of Vitelline
Protein B as a Microencapsulating Additive", by inventors
Ficht, et al., currently pending, which claims benefit under
35 U.S.C. §119(e) of provisional application U.S. Ser. No.
60/530,721, filed Dec. 18, 2003. The contents of which are
incorporated by reference herein in their entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
The government may own rights in the present invention
pursuant to grant number NCC-1-02038 from the National
Aeronautics and Space Administration (NASA); contract
#0300125 from the US Geological Survey, Department of
the Interior, National Park Service; and contract#DAMD17-
95-C-5048 from the U.S. Army Medical Research and
Materiel Command.
FIELD OF THE INVENTION
The invention relates to compositions and methods for
extended release encapsulation using additives, and more
particularly, to vitelline proteins as microencapsulation addi-
tives and uses thereof.
INCORPORATION-BY-REFERENCE OF
MATERIALS FILED ON COMPACT DISC
The present application includes a Sequence Listing
which has been submitted in ASCII format via EFS-Web and
is hereby incorporated by reference in its entirety. Said
ASCII copy, created on Jul. 26, 2016, is named
TAMU1006_seq_listing.txt and is 5K bytes in size.
BACKGROUND OF THE INVENTION
Without limiting the scope of the invention, its back-
ground is described in connection with polymeric encapsu-
lation of compounds.
The encapsulation of pharmaceuticals and other com-
pounds is of continuing interest, both in industry and in
academia. Encapsulation may be used to modify the time-
release properties of a material, to alter the solubility of a
material and/or to provide other desirable property modifi-
cations. Polymers, biopolymers and peptides have been
explored for their suitability as microencapsulation agents.
Microcapsules include, generally, a core material (liquid
or solid) encased in a specialized coating. Microencapsula-
tion technology has found widespread use in the pharma-
ceutical area, for example, coating of drugs to extend or
delay their release or target their release to a specific area of
the digestive tract. Other interesting applications include
encapsulation of ink in carbonless carbon paper, encapsu-
lation of perfumes in ` scratch and snilr types of promotion-
als and encapsulation of living pancreatic cells to treat
diabetes. In the case of living cells, the pore size of the
microcapsule is selected to prevent the passage of host
antibodies while allowing the free exchange of insulin and
2
glucagon. Microcapsules have also found application in the
food, cleaning, adhesives, fertilizers and aerospace indus-
tries to name a few.
Albumin has been used in the preparation of microcap-
5 sules. Two technologies have been used—coacervation, or
oil in water emulsions. These techniques have been the
source of many publications, including Zimmer et al. (7.
Controlled Release 33: 31-46 (1995)); Cremers et al. (Bio-
materials 15(1): 38-48 (1994)); Deasy (Microencapsulation
10 
and Related Drug Processes; Marcel Dekker, Inc., NY
(1984)); and Tomlinson, E. and Burger, J. J. Methods Enzy-
mol. 112: 27-43 (1985)). Despite the efforts made towards
developing microencapsulation methods, there still exists a
15 need for novel and effective materials for the encapsulation
of various materials.
SUMMARY OF THE INVENTION
20 The compositions and methods of the present invention
include, generally, an encapsulation additive comprising
between about 0.1 to about 30 percent isolated and purified
vitelline protein B. The present inventors recognized that a
key aspect of trematode infection and survival is the avoid-
25 ance of host immune responses. Studies as to the causes for
evasion of host immune surveillance led to the isolation and
characterization of proteins from trematode eggshells. Upon
isolation of the genes for the trematode proteins, vitelline
protein A (vpA), vitelline protein B (vpB) and vitelline
30 protein C (vpQ and isoforms of the same, it was discovered,
as disclosed herein that the vpB protein, in particular, is
stable at a wide range of pHs, is protease resistant and
non-immunogenic. As such, the present investigators used
the vpB protein as an additive for the encapsulation and
35 extended release of, small molecules, antigens and the like.
More particularly, the encapsulation additive of the pres-
ent invention may include the vitelline protein B from a
Trematode sp. The additive is generally non-antigenic, is
resistant to acid and base pH or both and may allow for the
40 slow release of an active agent to between about 1 hour to
about to about 8 hours, between about 1 hour to about 2
weeks, and between about 1 hour to about 6 months.
Examples of the one or more active agents may include a
pharmaceutical agent, an enzyme, a cytokine, a growth
45 promoting agent, an antibody, an antigen, a vaccine, a cell,
a live-attenuated pathogen, a heat-killed pathogen, a virus, a
bacteria, a fungi, a peptide, a carbohydrate, a nucleic acid,
a lipid, mixtures and combinations thereof. The vitelline
protein B may be formed into a capsule when combined by
50 coacervation, added into an oil-and-water emulsion, lipo-
somes, spray freezing, spray drying, as a component of an
alginate microcapsule or combinations thereof. Other
examples of active agents include: protein, peptide, carbo-
hydrate, polysaccharide, glycoprotein, lipid, hormone,
55 growth factor, cytokine, interferon, receptor, antigen, aller-
gen, antibody, substrate, metabolite, cofactor, inhibitor,
drug, pharmaceutical, nutrient, toxin, poison, explosive,
pesticide, chemical warfare agent, biowarfare agent, biohaz-
ardous agent, infectious agent, prion, radioisotope, vitamin,
6o heterocyclic aromatic compound, carcinogen, mutagen, nar-
cotic, amphetamine, barbiturate, hallucinogen, waste prod-
uct, contaminant, heavy metal, virus, bacterium, Salmonella,
Streptococcus, Brucella, Legionella, E. coli, Guardia, Cryp-
tosporidium, Rickettsia, spore, mold, yeast, algae, amoebae,
65 dinofiagellate, unicellular organism, pathogen, cell, combi-
nations and mixtures thereof, that is encapsulated in a mixed
release polymer comprising between about 0.1 to about 26,
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about 0.1 to about 30, or even about 0.1 to about 90 weight
percent isolated and purified recombinant vitelline protein
B.
Yet another embodiment of the present invention may be
a mixed release pharmaceutical formulation with one or
more active agents microencapsulated in a mixed release
polymer and between about 0.1 to 26 percent isolated and
purified vitelline protein B. A polymer selected from the
group consisting of cellulose, ethylcellulose, methylcellu-
lose, propylcellulose, methoxypropylcellulose, cellulose
nitrate, poly(vinyl alcohol), poly(vinyl chloride), polysty-
rene, polyethylene, polypropylene, poly(ethylene-co-vinyl
acetate), poly(hydroxybutyric acid), poly(hydroxyvalerianic
acid-co-hydroxybutyric acid), poly(lactic acid), poly(gly-
colic acid), poly(lactic acid-co-glycolic acid),
poly(epsilon (-caprolactones), poly(epsilon(-caprolactone-
co-DL-lactic acid), poly(maleic anhydride), polyamides,
gelatin, chitosan, collagen, poly(hydroxyalkyl)-L-gluta-
mines, poly(gamma(-ethyl-L-glutaminate-co-glutamic
acid), poly(L-leucine-co-L-aspartic acid), poly(proline-co-
glutamic acid), poly(alkyl 2-cyanoacrylates), polyurethanes,
poly(methyl methacrylate), poly(methyl methacrylate-co-
methacrylic acid) and poly(methacrylate-co-hydroxypropyl
methacrylate).
Other examples of active agents may include a pharma-
ceutical agent, an enzyme, a cytokine, a growth promoting
agent, an antibody, an antigen, a vaccine, a cell, a live-
attenuated pathogen, a heat-killed pathogen, a virus, a bac-
teria, a fungi, a peptide, a carbohydrate, a nucleic acid, a
lipid, mixtures and combinations thereof.
The present invention may also include a method of
encapsulation that includes the steps of mixing one or more
active agents with one or more cross-linkable monomers and
a vitelline protein B, wherein the vitelline protein B modifies
the release profile of the one or more active agents. Alter-
natively, the method of making an extended release formu-
lation may include the steps of mixing one or more active
agents with alginate and vitelline protein B, wherein the
vitelline protein B modifies the release profile of one or more
of the active agents. The one or more active agents are
released for between about 1 hour to about 8 hours, between
about 1 hour to about 2 weeks, and between about 1 hour to
about 6 month and the vitelline protein B comprises a
Trematode sp. protein that is non-antigenic, is resistant to
acid pH, resistant to basic pH or combinations thereof. The
method may also include the step of mixing poly-L lysine
with the vitelline protein B, wherein the ratio of the poly-L
lysine to vitelline protein B is between about 30:70 to 70:30
weight to weight.
Yet another embodiment of the present invention is a
mixed release pharmaceutical formulation in which one or
more one or more pharmaceutical agents is encapsulated in
a mixed release polymer comprising between about 0.1 to 26
weight percent isolated and purified vitelline protein B.
Examples of pharmaceutical agents include: steroids, respi-
ratory agents, sympathomimetics, local anesthetics, antimi-
crobial agents, antiviral agents, antifungal agents, antihel-
minthic agents, insecticides, antihypertensive agents,
antihypertensive diuretics, cardiotonics, coronary vasodila-
tors, vasoconstrictors, (3-blockers, antiarrhythmic agents,
calcium antagonists, anti-convulsants, agents for dizziness,
tranquilizers, antipsychotics, muscle relaxants, drugs for
Parkinson's disease, respiratory agents, hormones, non-
steroidal hormones, antihormones, vitamins, antitumor
agents, miotics, herb medicines, antimuscarinic, inter-
fereons, immunokines, cytokines, muscarinic cholinergic
blocking agents, mydriatics, psychic energizers, Immoral
4
agents, antispasmodics, antidepressant drugs, anti-diabetics,
anorectic drugs, anti-allergenics, decongestants, expecto-
rants, antipyretics, antimigrane, anti-malarials, anti-ulcer-
ative, peptides, anti-estrogen, anti-hormone agents, antiulcer
5 agents, anesthetic agent, drugs having an action on the
central nervous system or combinations thereof. The poly-
mer may be a biocompatible and/or biodegradable polymer
selected from: poly(ethylene glycol), poly(ethylene oxide),
poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethylox-
io azoline), poly(ethylene oxide)-co-poly(propylene oxide)
block copolymers, polysaccharides, carbohydrates, proteins
and combinations thereof.
A mixed release pharmaceutical formulation using the
vpB additive of the present invention may include one or
15 more active agents selected from protein, peptide, carbohy-
drate, polysaccharide, glycoprotein, lipid, hormone, growth
factor, cytokine, interferon, receptor, antigen, allergen, anti-
body, substrate, metabolite, cofactor, inhibitor, drug, phar-
maceutical, nutrient, toxin, poison, explosive, pesticide,
20 chemical warfare agent, biowarfare agent, biohazardous
agent, infectious agent, prion, radioisotope, vitamin, hetero-
cyclic aromatic compound, carcinogen, mutagen, narcotic,
amphetamine, barbiturate, hallucinogen, waste product, con-
taminant, heavy metal, virus, bacterium, Salmonella, Strep-
25 tococcus, Brucella, Legionella, E. coli, Guardia, Cryptospo-
ridium, Rickettsia, spore, mold, yeast, algae, amoebae,
dinoflagellate, unicellular organism, pathogen, cell, combi-
nations and mixtures thereof, that is encapsulated in a mixed
release polymer and between about 0.1 to 26 weight percent
30 isolated and purified vitelline protein B.
Yet another embodiment of the present invention is a
vaccine in which one or more antigens are encapsulated in
a mixed release with between about 0.1 to 26 weight percent
isolated and purified vitelline protein B. The antigen may be
35 selected from: protein, peptide, carbohydrate, polysaccha-
ride, glycoprotein, lipid, hormone, growth factor, cytokine,
interferon, receptor, antigen, allergen, antibody, substrate,
metabolite, cofactor, inhibitor, drug, pharmaceutical, nutri-
ent, toxin, poison, explosive, pesticide, chemical warfare
4o agent, biowarfare agent, biohazardous agent, infectious
agent, prion, radioisotope, vitamin, heterocyclic aromatic
compound, carcinogen, mutagen, narcotic, amphetamine,
barbiturate, hallucinogen, waste product, contaminant,
heavy metal, virus, bacterium, Salmonella, Streptococcus,
45 Brucella, Legionella, E. coli, Guardia, Cryptosporidium,
Rickettsia, spore, mold, yeast, algae, amoebae, dinoflagel-
late, unicellular organism, pathogen, cell, combinations and
mixtures thereof. Yet another embodiment of the present
invention is an adhesive having between about 1 to about 90
50 percent isolated and purified vitelline protein B.
The vpB additive and methods disclosed herein may be
used for the micro and nano-encapsulation of a number of
active agents, e.g., peptides, proteins, aptamers, oligonucle-
otides, carbohydrates, lipids, glycolipids, glycoproteins,
55 anti-obesity drugs, nutraceuticals, cortico steroids, elastase
inhibitors, analgesics, anti-fungals, antibiotics, antibodies,
antigens, oncology therapies, anti-emetics, analgesics, car-
diovascular agents, anti-inflammatory agents, antigens, anti-
helmintics, anti-arrhythmic agents, antibiotics, antibodies,
6o anticoagulants, antidepressants, antidiabetic agents, antiepi-
leptics, antihistamines, antihypertensive agents, antimusca-
rinic agents, antimycobacterial agents, antineoplastic agents,
immunosuppressants, antithyroid agents, antiviral agents,
anxiolytics, sedatives, astringents, beta-adrenoceptor block-
65 ing agents, blood products and substitutes, cardiac inotropic
agents, contrast media, cortico steroids, cough suppressants,
diagnostic agents, diagnostic imaging agents, diuretics, dop-
US 9,555,073 B2
aminergics, haemostatics, immunological agents (cytokines,
lymphokines), lipid regulating agents, muscle relaxants,
parasympathomimetics, parathyroid calcitonin and biphos-
phonates, prostaglandins, radio-pharmaceuticals, sex hor-
mones, insecticides, anti-allergic agents, stimulants and ano-
retics, sympathomimetics, thyroid agents, vasodilators, and
xanthines, and derivatives, salts and combinations thereof.
The skilled artisan will recognize that a number of agents
may be used and/or delivered in combination with the
present invention, including, organic or inorganic molecules
(small or large), second messengers, nucleic acids (natural,
non-natural and derivatives thereof), amino acids (natural,
non-natural and derivatives thereof), carbohydrates (mono-
meric or oligomeric), lipids, cells, cell fragments, glycopro-
teins, nutrients, vitamins, etc.
The vpB and related proteins of the present invention may
also be used in a method of treating an animal, the method
in which the mixed release formulation of the present
invention is administered to a mammal. In an alternative
embodiment, the vpB protein may also be used as a bent core
mesogen piezoelectric component.
BRIEF DESCRIPTION OF THE FIGURES
For a more complete understanding of the features and
advantages of the present invention, reference is now made
to the detailed description of the invention along with the
accompanying figures and in which:
FIG. 1 is a map that summarizes the divergence of amino
acid sequence between vpB family members: hatched lines
indicate areas of highly divergent amino acid sequence;
FIG. 2 is a graph that shows the release of a small
molecule, [3H] glycine, encapsulated using the additive of
the present invention;
FIG. 3 is a graph that shows the antibody titer of mice
treated via subcutaneous injection of encapsulated tetanus
toxoid;
FIG. 4 is a graph that shows the antibody titer of mice
treated via subcutaneous injection with botulinum toxin
encapsulated using the present invention and delivered as a
depot;
FIG. 5 is a graph that shows the immune response to doses
of botulinum neurotoxin A, fragment C trapped in the
composite capsule was dose dependent;
FIG. 6 is a graph that shows the antibody response of six
mice injected subcutaneously with encapsulated TT (tetanus
toxoid) composite capsules;
FIG. 7 is a graph that shows cellular immune response as
measured by tritium uptake for the same groups as FIG. 6 at
21 weeks;
FIG. 8 is a graph that shows the results obtained from Red
deer vaccination studies;
FIG. 9 is a graph that shows the kinetics of Immoral
immunity with subcutaneous vaccination of the present
invention;
FIG. 10 is a graph of serum antibody levels in Brucella
melitensis immunized mice; and
FIG. 11 shows the fluorescence profile of green fluores-
cent protein released over a one week period as determined
through SDS polyacrylamide gel electrophoresis and fluo-
rescence analysis. Lane I illustrates green fluorescent pro-
tein (gfp) released from an alginate capsule type I in 3 hours,
lane 2, 24 hours and lane 3, 7 days.
DETAILED DESCRIPTION OF THE
INVENTION
While the making and using of various embodiments of
the present invention are discussed in detail below, it should
T
be appreciated that the present invention provides many
applicable inventive concepts that can be embodied in a
wide variety of specific contexts. The specific embodiments
discussed herein are merely illustrative of specific ways to
5 make and use the invention and do not delimit the scope of
the invention.
To facilitate the understanding of this invention, a number
of terms are defined below. Terms defined herein have
meanings as commonly understood by a person of ordinary
io skill in the areas relevant to the present invention. Terms
such as "a", "an" and "the" are not intended to refer to only
a singular entity, but include the general class of which a
specific example may be used for illustration. The terminol-
ogy herein is used to describe specific embodiments of the
15 invention, but their usage does not delimit the invention,
except as outlined in the claims.
The term "additive" as used herein is used to describe vpB
protein, variants thereof, and proteins and peptides that have
a similar protein composition to produce encapsulants that
20 affect the release of an agent trapped in or about the additive,
e.g., when the additive is mixed with a polymeric or other
composition to form a micro or nanocapsule. It has been
found, as described in detail hereinbelow, that the Vitelline
protein B is a member of a family of proteins with variable
25 sequences, however, the amino acid composition is fixed.
The Vitelline protein B may be closed and/or isolated by
purification from, e.g., Fasciola hepatica. Alternatively, the
Vitelline protein B may be made synthetically, by recombi-
nant methods and combinations thereof.
30 The term "immediate release" as used herein is used to
describe a release profile to effect delivery of an active as
soon as possible, that is, as soon as practically made avail-
able to an animal, whether in active form, as a precursor
and/or as a metabolite. Immediate release may also be
35 defined functionally as the release of over 80 to 90 percent
(%) of the active ingredient within about 60, 90, 100 or 120
minutes or less.
The terms "extended release" and "delayed release" as
used herein is used to define a release profile to effect
4o delivery of an active over an extended period of time,
defined herein as being between about 60 minutes and about
2, 4, 6 or even 8 hours. Extended release may also be defined
functionally as the release of over 80 to 90 percent (%) of the
active ingredient after about 60 minutes and about 2, 4, 6 or
45 even 8 hours. Extended release as used herein may also be
defined as making the active ingredient available to the
patient or subject regardless of uptake, as some actives may
never be absorbed by the animal. Various extended release
dosage forms may be designed readily by one of skill in art
5o as disclosed herein to achieve delivery to both the small and
large intestines, to only the small intestine, or to only the
large intestine, depending upon the choice of coating mate-
rials and/or coating thickness.
"Extended release" and "delayed release" formulations
55 may be prepared and delivered using the Vitelline protein B
or variants thereof to control the release of an agent. The
Vitelline protein B protein may act alone or in combination
with other compounds that delay release of an active, e.g., a
coating, a capsule or mixture with controlled, delayed or
60 extended release polymers. Any coatings should be applied
to a sufficient thickness such that the entire coating does not
dissolve in the gastrointestinal fluids at pH below about 5,
but does dissolve at pH about 5 and above. It is expected that
any anionic polymer exhibiting a pH-dependent solubility
65 profile can be used as an enteric coating in the practice of the
present invention to achieve delivery to the lower gastroin-
testinal tract. Polymers and compatible mixtures thereof
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may be used to provide the coating for the delayed or the
extended release of active ingredients, and some of their
properties, include, but are not limited to: shellac, also called
purified lac, a refined product obtained from the resinous
secretion of an insect. This coating dissolves in media of
pH>7.
As used herein, the term "enveloped pharmaceutical"
means a capsule, a suppository, a gel cap, a softgel, a
lozenge, a sachet or even a fast dissolving wafer. As used
herein the term "carrier" is used to describe a substance,
whether biodegradable or not, that is physiologically accept-
able for human or animal use and may be pharmacologically
active or inactive.
The vpB additive of the present invention may be used in
conjunction with a wide variety of dosage forms, e.g.,
solution, suspension, cream, ointment, lotion, capsule,
caplet, softgel, gelcap, suppository, enema, elixir, syrup,
emulsion, film, granule, gum, insert, jelly, foam, paste,
pastille, pellet, spray, troche, lozenge, disk, magma, poul-
tice, or wafer and the like.
The vpB additive of the present invention may be used to
delivery active pharmaceutical agents. As used herein,
"pharmaceutically" and/or "pharmacologically acceptable"
refer to molecular entities and/or compositions that do not
produce an adverse, allergic and/or other untoward reaction
when administered to an animal, as appropriate. One distinct
advantage of vpB is that it does not generally cause an
adverse, allergic and/or other untoward reaction when
administered to an animal.
As used herein, "pharmaceutically acceptable carrier"
may include any and/or all solvents, dispersion media,
coatings, antibacterial and/or antifungal agents, isotonic
and/or absorption delaying agents and/or the like. The use of
such media and/or agents for pharmaceutical active sub-
stances is well known in the art. Except insofar as any
conventional media and/or agent is incompatible with the
active ingredient, its use in the therapeutic compositions is
contemplated. Supplementary active ingredients can also be
incorporated into the compositions. For administration,
preparations should meet sterility, pyrogenicity, general
safety and/or purity standards as required by FDA Office of
Biologics standards.
As used herein, the term "therapeutically effective dos-
age" is used to describe the amount that reduces the amount
of symptoms of the condition in the infected subject by at
least about 20%, more preferably by at least about 40%,
even more preferably by at least about 60%, and still more
preferably by at least about 80% relative to untreated
subjects. Often, for pediatric doses the amount will be half
or less of the adult dose. For example, the efficacy of a
compound may be evaluated in an animal model system that
may be predictive of efficacy in treating the disease in
humans. Bioactive compounds are administered at a thera-
peutically effective dosage sufficient to treat a condition
associated with a condition in a subject.
The terms "amount," "pharmaceutically effective
amount" and "therapeutically effective amount" as used
herein refer to a quantity or to a concentration as appropriate
to the context. The amount of an active agent or drug that
constitutes a pharmaceutically or therapeutically effective
amount varies according to factors such as the potency of the
particular drug, the route of administration of the formula-
tion, and the mechanical system used to administer the
formulation as will be known to the skilled artisan. For
example, a pharmaceutically or therapeutically effective
amount is that dosage of active agents that when released is
sufficient to effect treatment, when administered to a mam-
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mal in need of such treatment. The therapeutically effective
amount will vary depending upon the subject and disease
condition being treated, the weight and age of the subject,
the severity of the disease condition, the manner of admin-
5 istration and the like, which can readily be determined by
one of ordinary skill in the art. The amount of active agent
and the need and amount of carriers and/or excipients are
disclosed, simply by way of example, by Remington's
Pharmaceutical Sciences, 19th edition, 1995, Ed. Gennaro,
io relevant portions incorporated herein by reference. The term
"treatment" or "treating" means any treatment of a disease
in a mammal, including: (i) preventing the disease, that is,
causing the clinical symptoms of the disease not to develop;
(ii) inhibiting the disease, that is, arresting the development
15 of clinical symptoms; and/or (iii) relieving the disease, that
is, causing the regression of clinical symptoms.
The additive of the present invention may be used in
conjunction with one or more carriers. As used herein the
terms "carrier" and "pharmaceutically acceptable carrier"
20 include any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents and the like. The use of such media and
agents for pharmaceutically active substances is well known
in the art. Except insofar as any conventional media or agent
25 is incompatible with the active ingredient, its use in the
therapeutic compositions is contemplated. Supplementary
active ingredients can also be incorporated into the compo-
sitions.
As used herein, the term "active ingredient(s)," "pharma-
30 ceutical ingredient(s)," "active agents" and "bioactive
agent" are defined as drugs and/or pharmaceutically active
ingredients. The present invention may be used to encapsu-
late, attach, bind or otherwise be used to affect the storage,
stability, longevity and/or release of any of the following
35 drugs as the pharmaceutically active agent in a composition.
One or more of the following bioactive agents may be
combined with the vpB additive disclosed herein: Analgesic
anti-inflammatory agents such as, acetaminophen, aspirin,
salicylic acid, methyl salicylate, choline salicylate, glycol
40 salicylate, 1-menthol, camphor, mefenamic acid, fluphe-
namic acid, indomethacin, diclofenac, alclofenac, ibuprofen,
ketoprofen, naproxene, pranoprofen, fenoprofen, sulindac,
fenbufen, clidanac, flurbiprofen, indoprofen, protizidic acid,
fentiazac, tolmetin, tiaprofenic acid, bendazac, bufexamac,
45 piroxicam, phenylbutazone, oxyphenbutazone, clofezone,
pentazocine, mepirizole and the like.
Drugs having an action on the central nervous system, for
example sedatives, hypnotics, antianxiety agents, analgesics
and anesthetics, such as, chloral, buprenorphine, naloxone,
5o haloperidol, fluphenazine, pentobarbital, phenobarbital,
secobarbital, amobarbital, cydobarbital, codeine, lidocaine,
tetracaine, dyclonine, dibucaine, cocaine, procaine, mepiva-
caine, bupivacaine, etidocaine, prilocalne, benzocaine, fen-
tanyl, nicotine and the like. Local anesthetics such as,
55 benzocaine, procaine, dibucaine, lidocaine and the like.
Antihistaminics or antiallergic agents such as, diphenhy-
dramine, dimenhydrinate, perphenazine, triprolidine, pyril-
amine, chlorcyclizine, promethazine, carbinoxamine,
tripelennamine, brompheniramine, hydroxyzine, cyclizine,
60 meclizine, clorprenaline, terfenadine, chlorpheniramine and
the like. Anti-allergenics such as, antazoline, methapyrilene,
chlorpheniramine, pyrilamine, pheniramine and the like.
Decongestants such as, phenylephrine, ephedrine, naphazo-
line, tetrahydrozoline and the like.
65 Antipyretics such as, aspirin, salicylamide, non-steroidal
anti-inflammatory agents and the like. Antimigrane agents
such as, dihydroergotamine, pizotyline and the like.
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Acetonide anti-inflammatory agents, such as hydrocorti-
sone, cortisone, dexamethasone, fluocinolone, triamcino-
lone, medrysone, prednisolone, flurandrenolide, prednisone,
halcinonide, methylprednisolone, fludrocortisone, corticos-
terone, paramethasone, betamethasone, ibuprophen,
naproxen, fenoprofen, fenbufen, flurbiprofen, indoprofen,
ketoprofen, suprofen, indomethacin, piroxicam, aspirin,
salicylic acid, diflunisal, methyl salicylate, phenylbutazone,
sulindac, mefenamic acid, meclofenamate sodium, tolmetin
and the like. Muscle relaxants such as, tolperisone, baclofen,
dantrolene sodium, cyclobenzaprine.
Steroids such as, androgenic steroids, such as, testoster-
one, methyltestosterone, fluoxymesterone, estrogens such
as, conjugated estrogens, esterified estrogens, estropipate,
17-R estradiol, 17-R estradiol valerate, equilin, mestranol,
estrone, estriol, 17(3 ethinyl estradiol, diethylstilbestrol, pro-
gestational agents, such as, progesterone, 19-norprogester-
one, norethindrone, norethindrone acetate, melengestrol,
chlormadinone, ethisterone, medroxyprogesterone acetate,
hydroxyprogesterone caproate, ethynodiol diacetate, nor-
ethynodrel, 17-a hydroxyprogesterone, dydrogesterone,
dimethisterone, ethinylestrenol, norgestrel, demegestone,
promegestone, megestrol acetate and the like.
Respiratory agents such as, theophilline and (32-adrener-
gic agonists, such as, albuterol, terbutaline, metaproterenol,
ritodrine, carbuterol, fenoterol, quinterenol, rimiterol,
solmefamol, soterenol, tetroquinol and the like. Sympath-
omimetics such as, dopamine, norepinephrine, phenylpro-
panolamine, phenylephrine, pseudoephedrine, amphet-
amine, propylhexedrine, arecoline and the like.
Antimicrobial agents including antibacterial agents, anti-
fungal agents, antimycotic agents and antiviral agents; tet-
racyclines such as, oxytetracycline, penicillins, such as,
ampicillin, cephalosporins such as, cefalotin, aminoglyco-
sides, such as, kanamycin, macrolides such as, erythromy-
cin, chloramphenicol, iodides, nitrofrantoin, nystatin,
amphotericin, fradiomycin, sulfonamides, purrolnitrin,
clotrimazole, miconazole chloramphenicol, sulfacetamide,
sulfamethazine, sulfadiazine, sulfamerazine, sulfamethizole
and sulfisoxazole; antivirals, including idoxuridine;
clarithromycin; and other anti-infectives including nitrofura-
zone and the like.
Antihypertensive agents such as, clonidine, a-methyl-
dopa, reserpine, syrosingopine, rescinnamine, cinnarizine,
hydrazine, prazosin and the like. Antihypertensive diuretics
such as, chlorothiazide, hydrochlorothiazide, bendoflumet-
hazide, trichlormethiazide, furosemide, tripamide, methyl-
clothiazide, penfluzide, hydrothiazide, spironolactone,
metolazone and the like. Cardiotonics such as, digitalis,
ubidecarenone, dopamine and the like. Coronary vasodila-
tors such as, organic nitrates such as, nitroglycerine, isosor-
bitol dinitrate, erythritol tetranitrate, and pentaerythritol
tetranitrate, dipyridamole, dilazep, trapidil, trimetazidine
and the like. Vasoconstrictors such as, dihydroergotamine,
dihydroergotoxine and the like. (3-blockers or antiarrhythmic
agents such as, timolol pindolol, propranolol and the like.
Humoral agents such as, the prostaglandins, natural and
synthetic, for example PGEI, PGE2a, and PGF2a, and the
PGEI analog misoprostol. Antispasmodics such as, atropine,
methantheline, papaverine, cinnamedrine, methscopolamine
and the like.
Calcium antagonists and other circulatory organ agents,
such as, aptopril, diltiazem, nifedipine, nicardipine, vera-
pamil, bencyclane, ifenprodil tartarate, molsidomine, cloni-
dine, prazosin and the like. Anti -convul sants such as,
nitrazepam, meprobamate, phenyloin and the like. Agents
for dizziness such as, isoprenaline, betahistine, scopolamine
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and the like. Tranquilizers such as, reserprine, chlorprom-
azine, and antianxiety benzodiazepines such as, alprazolam,
chlordiazepoxide, clorazeptate, halazepam, oxazepam,
prazepam, clonazepam, flurazepam, triazolam, lorazepam,
5 diazepam and the like.
Antipsychotics such as, phenothiazines including thiopro-
pazate, chlorpromazine, triflupromazine, mesoridazine, pip-
erracetazine, thioridazine, acetophenazine, fluphenazine,
perphenazine, trifluoperazine, and other major tranquilizers
io such as, chlorprathixene, thiothixene, haloperidol, bromperi-
dol, loxapine, and molindone, as well as, those agents used
at lower doses in the treatment of nausea, vomiting and the
like.
Drugs for Parkinson's disease, spasticity, and acute
15 muscle spasms such as levodopa, carbidopa, amantadine,
apomorphine, bromocriptine, selegiline (deprenyl), trihexy-
phenidyl hydrochloride, benztropine mesylate, procyclidine
hydrochloride, baclofen, diazepam, dantrolene and the like.
Respiratory agents such as, codeine, ephedrine, isoprotere-
2o nol, dextromethorphan, orciprenaline, ipratropium bromide,
cromglycic acid and the like. Non-steroidal hormones or
antihormones such as, corticotropin, oxytocin, vasopressin,
salivary hormone, thyroid hormone, adrenal hormone, kal-
likrein, insulin, oxendolone and the like.
25 Vitamins such as, vitamins A, B, C, D, E and K and
derivatives thereof, calciferols, mecobalamin and the like for
dermatologically use. Enzymes such as, lysozyme, uroki-
naze and the like. Herb medicines or crude extracts such as,
Aloe vera and the like.
30 Antitumor agents such as, 5-fluorouracil and derivatives
thereof, krestin, picibanil, ancitabine, cytarabine and the
like. Anti-estrogen or anti-hormone agents such as, tamox-
ifen or human chorionic gonadotropin and the like. Miotics
such as pilocarpine and the like.
35 Cholinergic agonists such as, choline, acetylcholine,
methacholine, carbachol, bethanechol, pilocarpine, muscar-
ine, arecoline and the like. Antimuscarinic or muscarinic
cholinergic blocking agents such as, atropine, scopolamine,
homatropine, methscopolamine, homatropine methylbro-
40 wide, methantheline, cyclopentolate, tropicamide, propan-
theline, anisotropine, dicyclomine, eucatropine and the like.
Mydriatics such as, atropine, cyclopentolate, homatro-
pine, scopolamine, tropicamide, eucatropine, hydroxyam-
phetamine and the like. Psychic energizers such as 3-(2-
45 aminopropy)indole, 3-(2-aminobutyl)indole and the like.
Antidepressant drugs such as, isocarboxazid, phenelzine,
tranylcypromine, imipramine, amitriptyline, trimipramine,
doxepin, desipramine, nortriptyline, protriptyline, amoxap-
ine, maprotiline, trazodone and the like. Anti-diabetics such
5o as, insulin, and anticancer drugs such as, tamoxifen, metho-
trexate and the like. Anorectic drugs such as, dextroamphet-
amine, methamphetamine, phenylpropanolamine, fenflu-
ramine, diethylpropion, mazindol, phentermine and the like.
Anti-malarials such as, the 4-aminoquinolines, alphamino-
55 quinolines, chloroquine, pyrimethamine and the like. Anti-
ulcerative agents such as, misoprostol, omeprazole, enprostil
and the like. Antiulcer agents such as, allantoin, aldioxa,
alcloxa, N-methylscopolamine methylsuflate and the like.
Antidiabetics such as insulin and the like.
60 For use with vaccines, one or more antigens, such as,
whole-organism, natural, attenuated, heat-killed, chemi-
cally-inactivated, synthetic, peptides and even T cell
epitopes peptides and the like. Some examples of the acro-
nym of these antigens names include, but not limited to,
65 LADE, DACE, MACE, etc.
The drugs mentioned above may be used in combination
as required. Moreover, the above drugs may be used either
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in the free form or, if capable of forming salts, in the form
of a salt with a suitable acid or base. If the drugs have a
carboxyl group, their esters may be employed. Acids may be
an organic acid, for example, methanesulfonic acid, lactic
acid, tartaric acid, fumaric acid, maleic acid, acetic acid, or
an inorganic acid, for example, hydrochloric acid, hydro-
bromic acid, phosphoric acid or sulfuric acid. The base may
be an organic base, for example, ammonia, triethylamine, or
an inorganic base, for example, sodium hydroxide or potas-
sium hydroxide. The esters mentioned above may be alkyl
esters, aryl esters, aralkyl esters and the like.
The present invention may be implanted into materials
that include sutures, tubes, sheets, adhesion prevention
devices, wound healing products, tissue healing agents and
other tissue or cell growth promoters that further enhance
the effectiveness of tissue regeneration. In addition, a volt-
age or current may be applied directly to the present inven-
tion at the repair, implant, transplant or reconstruction site.
Polymers or other molecules with piezoelectric or electri-
cally conducting properties may also be incorporated into
the present invention. Several electroactive polymers exist
including piezoelectric (e.g., polyvinylidene fluoride) and
electrically conducting materials (e.g., polypyrrole (PP), and
polythiophene). Since piezoelectric materials depend on
small mechanical deformations to produce transient surface
charges, the level and duration of focused stimulation cannot
be controlled. In contrast, electrically conducting polymers
readily permit external control over both the level and
duration of stimulation. Thus strategies designed to enhance
the regeneration of a responsive cell might employ electri-
cally conducting polymers. For diagnostic purposes, the
present invention may be incorporated not only with mol-
ecules containing active species but also with one or more
detectable agents or molecules that allows for the diagnosis,
monitoring, and/or prophylactic measures. Examples of suit-
able detectable agents include dyes, labels, metals, detection
devices, and electronic chips.
The extended release microencapsulated active agents
may be formed into compositions suitable for injectable use
with the Vitelline protein B additive to encapsulate the active
followed by dispersion in, e.g., sterile aqueous solutions
and/or dispersions; formulations including sesame oil, pea-
nut oil and/or aqueous propylene glycol; and/or sterile
powders for the extemporaneous preparation of sterile
injectable solutions and/or dispersions. In all cases the form
must be sterile and/or must be fluid to the extent that easy
syringability exists. It must be stable under the conditions of
manufacture and/or storage and/or must be preserved against
the contaminating action of microorganisms, such as bacte-
ria and/or fungi.
Solutions of the active compounds as free base and/or
pharmacologically acceptable salts may be prepared in water
suitably mixed with a surfactant, such as hydroxypropylcel-
lulose. Dispersions may also be prepared in glycerol, liquid
polyethylene glycols, and/or mixtures thereof and/or in oils.
Under ordinary conditions of storage and/or use, these
preparations contain a preservative to prevent the growth of
microorganisms.
Sterile injectable solutions are prepared by incorporating
the active compounds in the required amount in the appro-
priate solvent with various of the other ingredients enumer-
ated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle that
contains the basic dispersion medium and/or the required
other ingredients from those enumerated above. In the case
of sterile powders for the preparation of sterile injectable
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solutions, the preferred methods of preparation are vacuum-
drying and/or freeze-drying techniques that yield a powder
of the active ingredient plus any additional desired ingredi-
ent from a previously sterile-filtered solution thereof. The
5 preparation of more, and/or highly, concentrated solutions
for direct injection is also contemplated, where the use of
dimethyl sulfoxide (DMSO) as solvent is envisioned to
result in extremely rapid penetration, delivering high con-
centrations of the active agents to a small tumor area.
10 Upon formulation, solutions will be administered in a
manner compatible with the dosage formulation and/or in
such amount as is therapeutically effective. The formulations
are easily administered in a variety of dosage forms, such as
the type of injectable solutions described above, but drug
15 release capsules and/or the like may also be employed.
For parenteral administration in an aqueous solution, for
example, the solution should be suitably buffered if neces-
sary and/or the liquid diluent first rendered isotonic with
sufficient saline and/or glucose. These particular aqueous
20 solutions are especially suitable for intravenous, intramus-
cular, subcutaneous and/or intraperitoneal administration. In
this connection, sterile aqueous media that may be employed
will be known to those of skill in the art in light of the
present disclosure. For example, one dosage could be dis-
25 solved in 1 ml of isotonic NaCl solution and/or either added
to 1000 ml of hypodermoclysis fluid and/or injected at the
proposed site of infusion, (see for example, "Remington's
Pharmaceutical Sciences" 15th Edition, pages 1035-1038
and/or 1570-1580). Some variation in dosage will necessar-
30 ily occur depending on the condition of the subject being
treated. The person responsible for administration will, in
any event, determine the appropriate dose for the individual
subject.
In addition to the compounds formulated for parenteral
35 administration, such as intravenous and/or intramuscular
injection, other pharmaceutically acceptable forms include,
e.g., tablets and/or other solids for oral administration;
liposomal formulations; time release capsules; and/or any
other form currently used, including cremes.
40 One may also use nasal solutions and/or sprays, aerosols
and/or inhalants in the present invention. Nasal solutions are
usually aqueous solutions designed to be administered to the
nasal passages in drops and/or sprays. Nasal solutions are
prepared so that they are similar in many respects to nasal
45 secretions, so that normal ciliary action is maintained. Thus,
the aqueous nasal solutions usually are isotonic and/or
slightly buffered to maintain a pH of 5.5 to 6.5. In addition,
antimicrobial preservatives, similar to those used in oph-
thalmic preparations, and/or appropriate drug stabilizers, if
5o required, may be included in the formulation.
Additional formulations that are suitable for other modes
of administration include vaginal suppositories and/or sup-
positories. A rectal suppository may also be used. Supposi-
tories are solid dosage forms of various weights and/or
55 shapes, usually medicated, for insertion into the rectum,
vagina and/or the urethra. After insertion, suppositories
soften, melt and/or dissolve in the cavity fluids. In general,
for suppositories, traditional binders and/or carriers may
include, for example, polyalkylene glycols and/or triglycer-
60 ides; such suppositories may be formed from mixtures
containing the active ingredient in the range of 0.5% to 10%,
preferably 1%-2%.
Oral formulations include such normally employed
excipients as, for example, pharmaceutical grades of man-
65 nitol, lactose, starch, magnesium stearate, sodium saccha-
rine, cellulose, magnesium carbonate and/or the like. These
compositions take the form of solutions, suspensions, tab-
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lets, pills, capsules, sustained release formulations and/or
powders. In certain defined embodiments, oral pharmaceu-
tical compositions will comprise an inert diluent and/or
assimilable edible carrier, and/or they may be enclosed in
hard and/or soft shell gelatin capsule, and/or they may be
compressed into tablets, and/or they may be incorporated
directly with the food of the diet. For oral therapeutic
administration, the active compounds may be incorporated
with excipients and/or used in the form of ingestible tablets,
buccal tables, troches, capsules, elixirs, suspensions, syrups,
wafers, and/or the like. Such compositions and/or prepara-
tions should contain at least 0.1% of active compound. The
percentage of the compositions and/or preparations may, of
course, be varied and/or may conveniently be between about
2 to about 75% of the weight of the unit, and/or preferably
between 25-60%. The amount of active compounds in such
therapeutically useful compositions is such that a suitable
dosage will be obtained.
The tablets, troches, pills, capsules and/or the like may
also contain the following: a binder, as gum tragacanth,
acacia, cornstarch, and/or gelatin; excipients, such as dical-
cium phosphate; a disintegrating agent, such as corn starch,
potato starch, alginic acid and/or the like; a lubricant, such
as magnesium stearate; and/or a sweetening agent, such as
sucrose, lactose and/or saccharin may be added and/or a
flavoring agent, such as peppermint, oil of wintergreen,
and/or cherry flavoring. When the dosage unit form is a
capsule, it may contain, in addition to materials of the above
type, a liquid carrier. Various other materials may be present
as coatings and/or to otherwise modify the physical form of
the dosage unit. For instance, tablets, pills, and/or capsules
may be coated with shellac, sugar and/or both. A syrup of
elixir may contain the active compounds sucrose as a
sweetening agent methyl and/or propylparabens as preser-
vatives, a dye and/or flavoring, such as cherry and/or orange
flavor.
The mixed release pharmaceutical formulations disclosed
herein may be administered, e.g., parenterally, intraperito-
neally, intraspinally, intravenously, intramuscularly, intrav-
aginally, subcutaneously, or intracerebrally. Dispersions
may be prepared in glycerol, liquid polyethylene glycols,
and mixtures thereof and in oils. Under ordinary conditions
of storage and use, these preparations may contain a pre-
servative to prevent the growth of microorganisms. The
proper fluidity may be maintained, for example, by the use
of a coating such as lecithin, by the maintenance of the
required particle size in the case of dispersion and by the use
of surfactants. Prevention of the action of microorganisms
may be achieved by various antibacterial and antifungal
agents, for example, parabens, chlorobutanol, phenol, ascor-
bic acid, thimerosal and the like. In many cases, it will be
preferable to include isotonic agents, for example, sugars,
sodium chloride, or polyalcohols such as mannitol and
sorbitol, in the composition. Prolonged absorption of the
injectable compositions may be brought about by including
in the composition an agent that delays absorption, for
example, aluminum monostearate or gelatin.
Sterile injectable solutions may be prepared by incorpo-
rating the therapeutic compound in the required amount in
an appropriate solvent with one or a combination of ingre-
dients enumerated above, as required, followed by filtered
sterilization. Generally, dispersions are prepared by incor-
porating the therapeutic compound into a sterile carrier that
contains a basic dispersion medium and the required other
ingredients from those enumerated above. In the case of
sterile powders for the preparation of sterile injectable
solutions, the methods of preparation may include vacuum
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drying, spray drying, spray freezing and freeze-drying that
yields a powder of the active ingredient (i.e., the therapeutic
compound) plus any additional desired ingredient from a
previously sterile-filtered solution thereof.
5 The bioactive may be orally administered, for example,
with an inert diluent or an assimilable edible carrier. The
therapeutic compound and other ingredients may also be
enclosed in a hard or soft shell gelatin capsule, compressed
into tablets, or incorporated directly into the subject's diet.
io For oral therapeutic administration, the therapeutic com-
pound may be incorporated with excipients and used in the
form of ingestible tablets, buccal tablets, troches, capsules,
elixirs, suspensions, syrups, wafers and the like. The per-
centage of the therapeutic compound in the compositions
15 and preparations may, of course, be varied as will be known
to the skilled artisan. The amount of the therapeutic com-
pound in such therapeutically useful compositions is such
that a suitable dosage will be obtained.
It is especially advantageous to formulate parenteral com-
20 positions in dosage unit form for ease of administration and
uniformity of dosage. Dosage unit form as used herein refers
to physically discrete units suited as unitary dosages for the
subjects to be treated; each unit containing a predetermined
quantity of therapeutic compound calculated to produce the
25 desired therapeutic effect in association with the required
pharmaceutical carrier. The specification for the dosage unit
forms of the invention are dictated by and directly dependent
on (i) the unique characteristics of the therapeutic compound
and the particular therapeutic effect to be achieved; and/or
30 (ii) the limitations inherent in the art of compounding such
a therapeutic compound for the treatment of a selected
condition in a subject.
Vitteline protein B (vpB) is one of three proteins used by
parasitic worms to produce an encapsulant to protect the
35 developing embryo. The protein eggshell is formed pre-
dominantly of vpB through the use of protein precursors
which become crosslinked during the maturation process
through the use of dihydroxphenylalanine residues. VpA and
vpC, found in small quantities in the eggshell, are believed
40 to be involved in deposition and spreading of vpB. As an
immature, uncured protein, vpB demonstrates adhesive
properties; as a fully cured protein it serves as a novel
sealant which is resistant to acids, bases, heat, light, dessi-
cation, and proteolysis. In addition the shell material is
45 biocompatible and non-antigenic. It has been found that
vpB's resistance to proteolysis makes it an ideal additive for
microcapsules and micro- and nanoparticles, extending par-
ticle life when introduced into an animal. The vpB protein
may also be used as a protein adhesive in aqueous environ-
50 ments.
Vitelline protein B is a member of a family of proteins
with variable sequences, however, the amino acid compo-
sition is fixed. The present inventors cloned and sequenced
two members of the vpB gene family and find their amino
55 acid sequence to vary only within the central 33% of the
gene sequence.
As shown in FIG. 1, the sequence varies, the amino acid
composition of the two vpBs (vpBI and vpB2) is very
similar; furthermore their amino acid composition is nearly
60 identical to that of the eggshell itself. As shown here the
amino terminal (N) ends of the proteins (approximately '/s)
and the carboxy terminal (C) ends of the proteins ('/s) are
identical when comparing the two amino acid sequences.
However the central one third of the two proteins diverge
65 significantly at the amino acid level (35%). This shuffling of
amino acids still preserves the amino acid composition and
the functionality of these materials.
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Table 1 summarizes the conservation of the amino acid
composition of two VpB proteins.
Purified vpB
AMINO ACID PROTEIN VpBl eDNA* VpB2 eDNA*
ASX 140 +4.3 158.1 134.0
THR 18 + 3.1 15.8 15.8
SER 52 +4.8 55.3 51.4
GLX 83 + 3.7 83.0 75.1
PRO 16 + 0.9 11.9 11.9
GLY 165 +4.6 150.2 154.2
ALA 69 + 2.4 71.1 71.1
CYS/2 0 0 0
VAL 9+2.1 7.9 4.0
MET 23 +4.2 23.7 23.7
ILE 5 + 1.0 4.0 0
LEU 38 + 1.4 35.6 35.6
DOPA 106 + 9.8
TYR 21 + 5.0 134.4 138.3
PHE 38 + 3.1 35.6 35.6
HIS 45 + 3.7 33.3 55.3
LYS 120 + 6.5 114.6 126.5
ARG 60 + 3.2 63.2 67.2
TRP 0 0 0
*values represent mature vpB exclusive of signal sequence
As such, the composition rather than the sequence of these
proteins is responsible for the properties of 1) resistance to
proteolysis and 2) adhesiveness.
Polymers containing catecholic groups are widespread in
nature and perform diverse functions. In microbial systems
the polymers consist of short peptides whose function is to
sequester ferric iron from the environment (Raymond and
Carrano 1979, Ong et al 1979). In marine invertebrates such
as mussels and tunicates the catecholic polymers are pro-
teins modified by the presence of dihydroxyphenylalanine
(DOPA) residues whose function is underwater sealant and
adhesive (Waite et al 1985, Waite 1986). The synthetic
counterparts of these polymers have found widespread
application in industry as semiconductors (Jaegfeldt et al
1983, Lau and Miller 1983), metal chelators (Pecoraro et al
1981), electrocatalysts (Degrand 1985) and adhesives (Pizzi
1985) to name a few. Additional interest in DOPA com-
pounds has been generated by the recent finding that DOPA
derivatives may act as redox cofactors at the active site in
amine oxidases (Janes et al 1990). The freshwater trema-
tode, Fasciola hepatica, produces a catecholic protein poly-
mer which functions as a structural protein in egg microen-
capsulation. The polymer is cross-linked and quinone-
tanned to produce a sclerotized egg case with extraordinary
properties.
Faciola hepatica is a digenetic trematode which encap-
sulates its eggs in a proteinaceous shell. The shells are a
prototypical microencapsulating system that protects Fas-
ciola eggs from the host natural defenses while allowing
uptake of essential nutrients and release of metabolic prod-
ucts. The long-term stability of this natural composite mate-
rial results from crosslinks formed by quinone tanning or
sclerotization of specialized eggshell proteins in which
tyrosine residues have been post-translationally modified to
3,4-dihydroxyphenylalanine (DOPA). The present inventors
purified and characterized the three major protein compo-
nents of the shell, vitelline proteins A, B and C (vpA, vpB,
and vpC). In addition, cDNAs encoding two variants of the
major eggshell component have been sequenced and
expressed as recombinant protein. The proteins encoded
consist of highly degenerate repeats of a hexapeptide
enriched in glycine and containing clusters of basic amino
acid residues as well as clusters of acidic residues.
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The vitelline proteins, natural encapsulating agents, offer
several advantages over materials in current use, such as
synthetic polymers and gelatin. (1) As recombinant proteins
they can be obtained in bulk with uniform and defined
5 characteristics. (2) The protein compositions can be geneti-
cally engineered to vary the density of tyrosine/DOPA
residues, or introduce cysteine residues and so control the
cross-linking characteristics and the resultant porosity and
stability of microcapsules. (3) The cross-linking agent is
to 
already integrated into the protein and need be only oxi-
dized, either spontaneously or with easily separable
reagents, to initiate curing. (4) the vitelline proteins are
poorly antigenic. (5) Though durable, cured protein is (ulti-
15 mately) biodegradable and non-toxic.
Synthetic microencapsulation. Proteins have enjoyed
extensive use as encapsulating agents and so there exist
numerous protocols which may be applied to vitelline pro-
tein microencapsulation. In essence, all approaches involve
20 the induction of a phase separation in a mixture of core
material and encapsulating agent such that the core is
efficiently engulfed by the encapsulating agent, usually
followed by stabilization of the microcapsule walls by low
molecular weight cross-linking agents such as glutaralde-
25 hyde. Phase separations are commonly induced by i)
manipulation of temperature, pH, salt or alcohol concentra-
tions; ii) addition of incompatible polymers; iii) liquid
coacervate formation; and iv) congealing or denaturation in
oil emulsions. Others approaches are suggested by the
3o biochemical properties of vpB, such as interfacial polymer-
ization at liquid/liquid interfaces or the stabilization of
liposomes encased in vitelline protein by covalent cross-
linking.
The present inventors have studied the mechanism by
35 which the worm microencapsulates in order to mimic that
process in vitro. The worm carries out the process of
microencapsulation by applying a film of eggshell precursor
protein to the surface of a lipoprotein layer or interface
formed in the lumen of Mehlis' gland, the site of eggshell
4o assembly. A catechol oxidase activity oxidizes the DOPA
residues of the eggshell precursor to DOPAquinone. The
highly reactive DOPAquinone is postulated to spontane-
ously form a number of types of chemical cross-links
although in this system lysine or histidine appear to be the
45 primary nucleophiles participating in cross-linking. Faith-
fully mimicking the worm's approach will therefore involve
the use of liposome encapsulation followed by spreading of
recombinant eggshell protein on the outer surface of the
liposome. A commercially available mushroom tyrosinase
50 may then be employed to crosslink the shell precursor
proteins in vitro and to cure the microcapsule.
Alternatively, coacervation methods based on gelatin
microcapsulation (simple coacervation) or gelatin/acacia
microencapsulation (complex coacervation) may be used.
55 Either approach eliminates the need to first encapsulate the
core material in a liposome prior to encapsulation with
vitelline protein.
One or more of vitelline proteins vpA, vpB, and vpC may
be contacted with an agent to be microencapsulated under
60 conditions suitable for microencapsulation. The agent can be
a peptide, protein, nucleic acid, pharmaceutical, or other
organic chemical compound. The nucleic acid and protein
sequence of vpB can be found at the NCBI database,
Accession No. M93024. Additionally, the vitelline proteins
65 may be modified by enzymatic or chemical post-transla-
tional modification. One example of such a modification is
the hydroxylation of one or more tyrosine residues. Addi-
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tionally, fragments of the vitelline proteins can be used in
place of, or in combination with the full length naturally
occurring proteins.
The following examples are included to demonstrate
preferred embodiments of the invention. It should be appre-
ciated by those of skill in the art that the techniques
disclosed in the examples which follow represent techniques
discovered by the inventors to function well in the practice
of the invention, and thus can be considered to constitute
preferred modes for its practice. However, those of skill in
the art should, in light of the present disclosure, appreciate
that many changes can be made in the specific embodiments
which are disclosed and still obtain a like or similar result
without departing from the scope of the invention.
EXAMPLES
Example 1
Purification and Characterization of Protein
Components of Shells
Documentation of Fasciola hepatica eggshell production
has historically included a quinone tanning process which
involves cross-linking of proteins containing catecholic
groups (Smyth and Clegg, 1959). However the nature of the
substrates involved in the cross-link and the structure of the
cross-link itself have been subjects for heated debate and
novel investigative approaches. Waite and Rice-Ficht dem-
onstrated the abundance of dihydroxyphenylalanine
(DOPA) in the shell producing glands of the worm (vitel-
laria) as well as in the shells themselves using a DOPA
specific reagent recognizing only monosubstituted 1,2 ben-
zenediols and producing a bright red chromophore. The
results were highly suggestive that DOPA is at least one of
the major substrates for oxidation and protein crosslinking.
Several DOPA-containing protein precursors of the shell
were subsequently purified and characterized. The three
major DOPA-containing proteins of the worm are rich in
glycine and DOPA and compose three major size classes of
70 kDa, 31 kDa and 17 kDa. Each protein also has a
distinctive amino acid composition with the 70 kDa protein
rich in ASX and ARG, the 31 kDa protein rich in LYS and
ASX the 17 kDa protein rich in HIS.
Example 2
Characterization of 31 kDa vpB Protein
The 31 kDa protein (vitelline protein B, vpB) has been
purified and characterized in detail (Waite and Rice-Ficht
1987; Waite and Rice-Ficht 1992, appendix 3; and Rice-
Ficht and Waite 1992, appendix 2). Sequence analysis of
tryptic peptides derived from this protein constituted the first
direct demonstration that DOPA residues were in fact a
component of the peptide backbone and were likely formed
through post-translational modification of tyrosine residues
of the precursor protein; this parallels observations in the
adhesive proteins of the marine mussel, Mytilis edulis,
(Waite and Tanzer 1980) but is quite distinct from other
mechanisms documented for quinone tanning such as that
employed by insects in the formation of cuticles and egg
cases (Richards 1978). The protein has an apparent molecu-
lar weight of 31,000, a pI of 7.4 and constitutes approxi-
mately 7% of the protein in adult Fasciola hepatica. Eleven
percent of the amino acid residues of the protein are DOPA
18
residues which ` disappear' during shell curing in vivo or
during treatment with mushroom polyphenol oxidase in
vitro.
5 Example 3
Isolation of cDNA Encoding vpB Protein
Isolation of cDNAs encoding the 31 kDa protein was
10 achieved using a combination of antibody selection and
hybridization with degenerate oligonucleotides (Rice-Ficht
and Waite 1992). The proteins encoded are approximately
30,900 daltons and bear a striking homology with the amino
acid composition of the purified protein. Sequencing of
15 cDNAs has revealed the presence of at least two distinct
mRNAs encoding vitelline protein B1 (vpBI) and vitelline
protein B2 (vpB2) which are markedly different in amino
acid sequence (33% variation) but quite similar in amino
acid compositions. Southern blot analysis also indicates the
20 presence of at least six gene copies for the 31 kDA protein
when vpBI is employed as a hybridization probe under
stringent conditions. These results led to a re-examination of
the apparently homogeneous 31 kDa protein and revealed
microheterogeneity and the presence of a family of proteins.
25 The electrophoretic microheterogeneity is attributed to i)
varying degrees of post-translational modification (TYR to
DOPA) and ii) the presence of mRNAs varying in primary
sequence (Waite and Rice-Ficht 1992, appendix 3). Frac-
tionation of the purified protein was achieved through C-8
30 reversed phase HPLC; and the fractions across the vpB peak
were subjected to amino acid analysis. All amino acids were
constant across the peak with the exception of tyrosine and
DOPA. DOPA residues were high on the leading edge of the
peak and declined with increasing acetonitrile concentra-
35 tion; the converse was true of tyrosine residues suggesting a
precursor-product relationship. N-terminal sequence analy-
sis of protein fractions across the peak indicates that all
proteins share the same N-terminus. This data taken alone
might indicate that the heterogeneity was due solely to
40 post-translational modification. However, extensive
sequencing of tryptic peptides has shown the presence of
peptides unique to the vpBI mRNA and to the vpB2 mRNA.
Both vpBI and vpB2 contain the N-terminal peptide
sequence defined through vpB peptide analysis. Southern
45 hybridization was carried out on duplicate filters using either
the vpBI gene as probe or an oligonucleotide which repre-
sents the N-terminus of all vpB proteins (data not shown).
There appear to be 6-7 structural genes for this family of
proteins while the N-terminal sequence is associated with
50 only one copy. However, the data derived from sequencing
vpBI and vpB2 indicates that at least two different tran-
scripts carry this N-terminal sequence. The possibilities for
this dichotomy are many but the likeliest explanations are
cis, trans or possibly differential RNA splicing are placing
55 the single N-terminal coding sequence on multiple tran-
scripts; this is being pursued. One approach to studying the
number of transcripts which bear the N-terminal sequence is
to employ PCR using RNA as substrate.
60 Example 4
Characterization of 17 kDa vpC Protein
Analysis of the 17 kDa eggshell protein (vitelline protein
65 C, vpC) has revealed a similar heterogeneity with the
presence of at least four distinct electrophoretic types.
Apparent molecular weights range from 16,000 to 18,500
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while pIs under denaturing conditions indicate the presence
of only two species of 6.89 and 6.99. A single amino
terminal peptide sequence is detectable and has been
employed as a tool for gene isolation using degenerate
oligomers. The amino acid composition of vpC is remark-
able in that DOPA (20%), histidine (20%), and glycine
(41-42%) comprise 80% of the amino acid residues in all
variants of the family. The bulk of the molecule is composed
of a (GLY-X)n repeat motif in which X is SER, DOPA or
HIS. The only feature which this protein shares with the 31
kDa protein is the presence of DOPA residues. The four or
more variants observed in the vpC family do not arise as a
result allelic differences between individuals since a survey
of six morphologically different worms indicates the pres-
ence of all vpC variants in each individual (Waite and
Rice-Ficht 1989).
Example 5
Temporal and Spatial Expression of RNA and
Proteins
Through the use of antisera specific for the 31 kDa protein
and through in situ hybridization it has been possible to
study the localization of expression of the major DOPA
protein. The use of a rabbit antisera raised against the
purified vpB in tissue localization studies has indicated a
high level of the protein within vitelline cells localized to the
vitelline glands at the worm periphery (Rice-Ficht 1992);
reactivity of antisera corresponds to the vitelline globules of
mature vitelline cells (Rice-Ficht and Waite, 1992; appendix
2) and is evident before vitelline cells pass into the vitelline
reservoir for delivery to Mehlis' gland, the site of shell
assembly. The 31 kDa protein is synthesized and stored in
vitelline granules of vitelline cells still residing in the
vitelline gland follicle.
In situ hybridization using the carboxyterminal 40% of
the vpBI gene agrees with the antibody localization data
(Rice-Ficht and Waite 1992). Transcripts encoding vpBI are
most abundant in the earliest form of mature vitelline cell
residing in the vitelline gland. The protein apparently enters
a pathway for regulated secretion and is stockpiled in
globules of the vitelline cell cytoplasm. A putative chemical
signal elaborated by Mehlis' gland triggers release of the
globules and the initiation of capsule assembly.
Example 6
Putative Models for Shell Assembly
Based on a body of histological and histochemical data
reviewed by Smyth and Clegg (1959), metabolic labeling
studies (reviewed by Rice-Ficht 1992) and the current
biochemical analysis of eggshell proteins, a biological and
biochemical model of shell assembly are proposed. In these
models all three shell precursor proteins are translated in the
extensive GER of the early vitelline cells and stockpiled in
globules prior to the time that the cells leave the follicle.
Nascent protein precursors are modified by a putative pro-
tein-specific tyrosyl hydroxylase to produce Dopa residues
in the protein backbone. The polyphenolic shell precursors
(Smyth 1954; Waite and Rice-Ficht 1989) and polyphenol
oxidase (Smyth 1954) are transported to the ootype and
packed away in vitelline cell globules. As vitelline cells
congregate in the ootype along with one fertilized ovum,
Mehlis' gland forms a lipoprotein membrane (Clegg 1965)
around the vitelline cell/egg mass which is followed by
20
release of globular material from the vitelline cells through
regulated secretion. As the globule contents spread on the
lipoprotein membrane, catechol oxidase becomes activated
and oxidation and crosslinking ensues. Dopa residues are
5 abundant in newly formed shells and shells of the proximal
uterus. As the shells pass through the uterus, Dopa residues
are consumed in the crosslinking reactions (as ascertained
through DOPA-specific staining; Waite and Rice-Ficht
1989) and the shells are completely ` cured' prior to extru-
10 sion.
Some clues to the role of individual proteins in shell
formation have presented themselves. VpB is the major shell
component by weight and is present in molar quantities
approximately 30 times that of vpA or vpC. Of the three
15 proteins studied only one, VpC, has substantial homology
with any published protein sequence; vpC shows strong
homology with the his-rich domain of high molecular
weight kininogen I whose function is to bind to negatively
charged surfaces and accelerate binding of other blood
20 clotting factors to that surface (Kitamura et al 1983). Based
on this homology, it is postulated that vpC is the first of the
shell proteins to associate with the lipoprotein layer, facili-
tating binding and dispersion of vpB and vpA during shell
formation.
25
Example 6
Characterization of the 70 kDa DOPA Containing
Protein of the Eggshell
30
The 70 kDa protein (vitelline protein A, vpA) is the last
of the three major DOPA containing protein precursors of
the eggshell remaining to be characterized. Preliminary
amino acid analysis has indicated a highASN/ASP (21%),
35 GLY (11%) and ARG (8%) content with 4% DOPA residues
and a substantial amount of unmodified tyrosine. One of the
future goals of the project is to compare in vitro modification
of the vpA, vpB and vpC with various polyphenol oxidases
in order to probe the factors governing modification of
40 individual tyrosine residues. Further characterization will
include analysis for microheterogeneity and limited peptide
sequencing.
45
Example 7
Purification and Characterization of the F hepatica
Catechol Oxidase
Present evidence suggests that catecholoxidase activity is
50 present in mature vitelline cells as well as eggshells of F
gigantica (Nellaiappan & Ramalingam, 1980), S. mansoni
(Seed and Bennett 1980), S. japonicum (Wang et al 1986),
and Parapleurus sauridae (Nellaiappan and Ramalingam
1980), where it presumably catalyzes the oxidation and
55 subsequent polymerization of the eggshell precursor pro-
teins to a quinone-tanned material. These studies, however,
do little more than confirm the presence of enzyme activity.
F. hepatica from freshly condemned bovine livers will be
obtained from the slaughterhouse in Sealy, Tex. and trans-
60 ported to the laboratory on dry ice. Extraction of soluble
enzyme activity from the vitellaria is complicated by at least
tree factors, a) vitellaria interdigitate with the digestive
diverticulum hence any extraction is likely to contain
enzyme with some contaminating proteases, b) like zymo-
65 gens, the catecholoxidases of insects, frog skin and mussels
(Waite 1985) are stockpiled in latent form prior to secretion,
and c) the catecholoxidases implicated in quinone-tanning
US 9,555,073 B2
21
reportedly have odd solubility requirements and commonly
become co-crosslinked to their substrates.
In order to address these concerns, enzyme extractions
will be done using buffers with a broad spectrum of protease
inhibitors, e.g., 1 M phenylmethylsulfonylfluoride, 10 mM
N-ethylmaleimide, 25 mM ethylenediaminetetraacetic acid
(EDTA). Good activation of other latent catecholoxidases
has been achieved with trypsin and, especially, chy-
motrypsin treatment. There is no fait accompli recipe for
solubilizing catecholoxidase activity from vitelline cells.
Wang, et al., (1986) extracted the enzyme from S. japonicum
with unbuffered 0.25 mM sucrose, others have utilized
unbuffered 0.25 M sucrose (Nellaiappan and Ramalingam,
1980) and 0.01 M sodium phosphate at pH 7.2 (Thangaraj et
al 1986) to solubilize enzyme from monogeneans. Unfortu-
nately, Seed et al., (1978) and Mansour (1958) report a
conflicting conclusion that catecholoxidase activity in F
hepatica and S. mansoni is not soluble in 0.1 M potassium
phosphate at pH 6.8. Clearly, many of these studies are of
marginal value and should be redone. Some precautions to
improve yields might be to use 1 M NaCl in the extraction
buffer. This improves recovery of enzyme from quinone-
tanned byssal threads (Waite 1986). Addition of potassium
cyanide or salicylaldoxime to crude extracts may reduce
premature oxidations by the enzyme, and use of borate as the
extraction buffer will complex (hence inactivate) intrinsic
substrates such as DOPA-containing proteins.
Example 8
Purification of Extracted Enzyme
Purification of the extracted enzyme will be attempted by
ion exchange chromatography and gel filtration. The assay
of catecholoxidase activity will be done using the assay
based on the formation of quinone-proline adducts
(Rzepecki and Waite 1989) and by measurement of Oz
consumption using an oxygen electrode (Duckworth &
Coleman 1970). The formation of quinone-proline adducts
is linear with time and results in a deep purple chromophore
(molar E3,,-8300 cm-'). Following the purification of the
enzyme, a physical characterization of the enzyme will
include molecular weight determination by gel filtration
using the appropriate range of standards, subunit molecular
weight determination by SDS PAGE, and prosthetic metal
determination by atomic absorption spectroscopy. All poly-
phenoloxidases known to date are copper proteins. Amino
acid composition will be performed following protein
hydrolysis according to Tsugita, et al, (1987). The N-termi-
nus of purified subunits will be sequenced by Edman gas
phase methodology (Ozols 1986). An alternate approach
will be an enzyme isolation from newly formed eggshells,
purified from the Fasciola uterus; complete digestion of the
shells with highly purified enzymes specific for DOPA
residues (from the marine organism Alteromonas, see below
in cross-link analysis) may release the catecholoxidase.
Since the enzyme is known to be active even in completely
cured eggshells this approach may yield some positive
results.
Enzyme-substrate kinetics will be a particular focus of
these studies. A comparison of the Michaelis-Menten behav-
ior of the vitelline and eggshell enzyme activities with
various synthetic mono- and diphenols and 02 will be
performed. In addition, DOPA-containing peptides derived
from protease digests of vitelline proteins B and C will be
employed as substrate. Effect of inhibitors, pH, and tem-
perature will be determined using the best substrate (highest
22
Vmax/Km) and heat denatured-controls. Use of intact pro-
teins as substrates is impractical due to the insolubility of
these without borate at physiological pH (Waite and Rice-
Ficht 1987).
5 In structures undergoing quinone tanning such as nascent
eggshells, it is not clear whether assembly occurs in a liquid
crystal or solid-state (Bouligand, 1985; Waite, 1985). The
amount of enzyme present would certainly have a bearing on
which of the states existed. In the liquid crystal, the enzyme
to 
would presumably have more freedom to move from one
crystalline precursor to another in the course of introducing
crosslinks. In the solid state, in contrast, enzyme activity
would be severely localized e.g., as in an eggbox and much
15 more of it would be required relative to the liquid crystal
model to effect crosslinking. Information about the concen-
tration of enzyme in the eggshells could thus indirectly at
least invalidate the liquid crystal or solid state models. If the
specific activity of catecholoxidase purified from vitelline
20 cells can be calculated, then in principle, the total amount of
active enzyme per mg eggshell protein can be estimated
according to Segel (1976). Recall that catecholoxidase activ-
ity persists in eggshells even after release of the egg from the
host (Smyth and Clegg 1959). The major assumption will be
25 that the specific activity of the enzyme is not drastically
altered once it becomes part of the eggshell. Total protein in
the eggshell will be quantitated by amino acid analysis
following hydrolysis. A corroborative estimate of the
amount of catecholoxidase in eggshells (based on the mol %
30 Cu detected in purified catecholoxidase) could be attempted
by doing atomic absorption measurements on hydrolyzed
eggshells. Here the assumption would be that all eggshell Cu
is from the catecholoxidase.
35 Numerous attempts to purify the trematode catechol oxi-
dase from freshly prepared worms applying techniques
successfully employed in M. edulis have been unsuccessful.
Techniques which successfully fractionate the enzyme often
lead to its inactivation before homogeneity can be achieved.
40 A new purification scheme involving the use of phase
partition with Triton X 114 (Bordier 1981; Sanchez-Ferrer
1989) will next be employed to fractionate and purify the
trematode enzyme. The enzyme plays a pivotal role in
eggshell assembly and its purification is a priority of the
45 project. Initial characterization of the trematode enzyme in
relatively crude preparations indicates it to be present in
stoichiometric rather than enzymatic quantities with respect
to the shell precursor proteins vpA, vpB and vpC. This raises
the distinct possibility that the enzyme is not only catalytic
5o but an integral part of the shell architecture becoming
crosslinked and immobilized during shell assembly. This
possibility is underscored by the fact that the enzyme may be
assayed in partially cured eggshells but never isolated (data
not shown). Histochemical evidence also suggests that the
55 enzyme is present in an inactive form even in newly formed
vitelline globules as an emulsion with the vpA, vpB and vpC
substrates. This provides the enzyme/substrate combination
in a premixed form prior to spreading and quinone tanning.
An alternate approach to enzyme purification by conven-
60 tional methods will be an amity purification scheme; this
approach would utilize antibody directed against recombi-
nant catechol oxidase coupled to cyanogen bromide acti-
vated sepharose beads. This approach is dependent upon
isolating the gene first and producing recombinant protein
65 from that gene (objective IIIB) Amity purification using
substrate covalently attached to beads (i.e. a methyl cat-
echol) might also be employed by a method analogous to
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that used for the purification of the Schistosoma glutathione-
S-transferase via bead-bound glutathione (Smith and John-
son 1988).
Example 9
Characterization of cDNAs Encoding the 17 kDa
Proteins
cDNAs were isolated from lambda gt10 and lambda gtl l
F hepatica libraries using hybridization and a degenerate
oligonucleotide probe. The N-terminal sequence of vpC was
employed to produce a 29-mer using inosine substitution at
the most degenerate positions in order to limit the number of
oligonucleotides in the mix (Ohtsuka et al 1985). The probe
was employed using tetramethylammonium chloride salts, a
method which provides a base composition-independent
hybridization (Wood et al 1985). The hybridization can be
controlled as a function of probe length only, enhancing
results when screening a complex library with a pool of
oligonucleotide probes. A number of cDNAs of 500-600
base pairs in length have been isolated and sequence is being
determined Sequencing is proceeding through application of
asymmetric polymerase chain reaction (Gyllensten and
Erlich 1988) directly from the selected lambda library
clones. Primers flanking cDNA insertion sites in the vector
are employed to amplify the DNA; following a brief extrac-
tion procedure to remove primers and nucleoside triphos-
phates the PCR product is subjected to sequencing with
standard dideoxy chain termination methods and T7 poly-
merase (Sanger and Coulson 1975). This method which
circumvents subcloning and other low-efficiency, time con-
suming procedures is being employed to examine the clones.
Example 10
Isolation and Characterization of cDNAs Encoding
the 70 kDa DOPA Protein
A similar approach may be used to isolate the vpBI and
vpB2 genes (Rice-Ficht and Waite 1992). Adult F hepatica
libraries have been constructed in this laboratory and include
cDNA libraries in lambda gt10 and lambda gtll and
genomic libraries in lambda 2001 and lambda DASH; each
has been used successfully for gene isolation. In view of the
low level antigenicity of vpB and vpC a dual approach to
gene isolation will be continued. Antibody will be raised to
the purified vpA and employed for cDNA isolation from the
lambda gtI l library (Davis and Young 1983). Limited pep-
tide sequencing will also be employed to define oligonucle-
otides for library screening and gene isolation. (Wood et al
1985).
Example 11
Isolation of the Gene Encoding Trematode Catechol
Oxidase
Lambda gtll libraries produce proteins as a fusion with
the 116 kDa b-galactosidase gene which may easily interfere
with proper folding and activity of the cloned enzyme. Early
attempts to carry out plaque assays with Arnow's reagent
(Arnow 1937) and 4-methyl catechol were unsuccessful due
to the solubility and instability of the chromophore pro-
duced. A modification of this protocol (Rzepecki and Waite
1989) producing a more intense color reaction was also
employed without success. An alternate approach using an
24
antibody (polyclonal) directed against the Mytilis edulis
catechol oxidase will be used to identify cloned trematode
enzyme in an expression library. Although catechol oxidases
investigated to date from various sources due not share
5 significant nucleotide or amino acid sequence homology,
secondary structures of the enzymes may be similar. Addi-
tionally, the trematode and mussel enzymes may be more
closely related in structure in view of the similarities in
substrates (protein-bound tyrosine) and processes in which
10 they participate.
Example 12
Selection of cDNAs Encoding Proteins Specific to
15 Mehlis' Gland from a Mehlis' Gland Specific
Expression Library
The Mehlis' gland constitutes the biochemical "black
box" of eggshell formation; among the functions attributed
20 to the gland are i) initial entrapment of 30 vitelline cells and
one ovum in a lipid bilayer (Wharton 1983), ii) signaling the
release of vitelline globules from the vitelline cells and iii)
activation of the catechol oxidase enzyme. In an effort to
identify additional products and processes involved with
25 shell manufacture and the production of the shell material,
a selection process will be carried out to identify proteins
manufactured only in Mehlis' gland. One interesting obser-
vation in our laboratory involves the finding that histochemi-
cally the uterine lining which interfaces with Mehlis' gland
30 contains a high concentration of membrane-bound alkaline
phosphatase. This is only one example of Mehlis' gland
specific products which may be isolated via the process
outlined here. We postulate that the presence of this enzyme
may be significant in relation to production of a phosphate
35 buffering system in the lumen of Mehlis' gland. pH may be
especially important in the spreading properties of histidine
rich proteins (i.e. vpC) since the imidazole pK is near pH 7.0
(Rice-Ficht 1992).
The production of a Mehlis' gland-specific cDNA library
40 will be carried out through the standard techniques first
applied to the manufacture of T cell-specific cDNA libraries
via "subtraction hybridization" (Hedrick et al 1984). For this
procedure flash frozen worms will be partially thawed and
the Mehlis' gland area from 50 worms excised and pooled;
45 the anterior portion or "head" of the worms will also be
pooled. The anterior portions are assumed to contain the
standard housekeeping genes found in all cell types and will
be used to remove unwanted RNA from the Mehlis' gland
preparation prior to cDNA synthesis. RNA will be extracted
50 from the tissues as described (Rice-Ficht and Waite 1992)
and a first strand cDNA synthesized using the Mehlis' gland
RNA as template. The cDNA will be hybridized to a
100-fold excess of head RNA and applied to hydroxyapatite.
The cDNA not retained by the column should be single-
55 stranded and unique to Mehlis' gland; a second cDNA strand
will be synthesized and the cDNA introduced into lambda
gtll and lambda gt10 for amplification. There are alternate
protocols to achieve the same objective including deletion
enrichment (Lamar and Palmer 1984) and a plus/minus
60 screening for standard cDNA libraries (Tedder et al 1988;
Zurita et al 1987).
cDNAs of interest will be located using antibody prepared
against excised Mehlis' gland or through a plus/minus
hybridization technique (Tedder et al 1988). The later relies
65 on screening duplicate plaque lifts from a cDNA library with
a radiolabeled cDNA representing first the tissue of interest
(i.e. Mehlis' gland) and secondly a tissue containing back-
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ground genes (i.e. the worm `head'). Plaques screening
positive with the gland probe and negative with the head
probe would be candidates for further study. The Mehlis'
gland specific nature of candidate sequences will be deter-
mined through i) in situ hybridization of the cloned segment
to worm sections to verify its presence in Mehlis' gland, ii)
production of recombinant protein against which polyclonal
and monoclonal antibody would be raised for tissue local-
ization studies or iii) sequencing of the cDNA through
polymerase chain reaction to perform a preliminary search
of the gene bank.
A limited success with the production of monoclonal
antibody against the shell precursor proteins prompted a
multifaceted approach to gene isolation. Additionally,
monoclonal antibody is often a poor reagent for clone
selection from expression libraries due to the fact that only
a single epitope is recognized by the antibody. The major
utility of monoclonal antibody will be in tissue localization
of proteins and fine structure mapping at the EM level.
Example 13
Analysis of the Metal Composition of Shells
Isolated Directly from the Trematode Uterus
The suggestion has been made that various metals are
associated with trematode vitellaria. The observation of
"calcareous corpuscles" within the mature vitelline cells of
Schistosoma mansoni which are rich not only in calcium but
in phosphorus and magnesium as well (Shaw and Erasmus
1984) is one of the strongest. Coupled with the fact that
DOPA residues have extraordinary binding constants for a
number of metals we propose to examine the metal content
of the vitelline cells of F hepatica as well as purified
eggshells for metal composition. Initial studies will be
carried out using electron probe microanalysis and energy
dispersive X-ray spectroscopy (Shaw and Erasmus 1984).
Element quantities as small as 10-18 g in subcellular struc-
tures may be probed (Hall 1979). Cryosections of adult
worms will be employed to minimize changes which might
occur with fixation. Both vitelline cells and eggshells within
the worm will be examined in cryosection although addi-
tional analysis of shells carefully purified from contents in
the absence of metal chelating agents will be performed. The
electron probe microanalysis technique is preferred initially
over more precise physical methods because it requires less
material and should serve well for initial survey purposes.
Example 14
Study of Metabolism and Deposition of Shell
Protein Components
Tissue culture techniques in trematodes have been largely
unsuccessful in the study of eggshell formation. Although
many aspects of worm metabolism are apparently preserved
under standard culture conditions shell deposition becomes
markedly aberrant after only minutes to hours in culture
(Clegg 1965; Smyth and Clegg 1959); free vitelline cells and
free globules of shell precursor material rapidly appear in
the proximal uterus during culture, a phenomenon which is
not observed in worms immediately after removal from the
host. Although egglaying by trematodes continues for hours
to days after introduction into culture, the process relies on
preformed RNA and protein since RNA production for shell
precursor ceases with introduction to culture (Reis et al
1989). The present inventors conducted culture of trema-
26
todes in fertilized chicken eggs as recently reported by Fried
(1989) for other genuses of flatworm and found that egg-
laying proceeds in an apparently normal fashion (i.e. a lack
of vitelline cells or free vitelline globules in the uterus) for
5 extended periods of time (tested up to ten days). Analysis of
culture worms for the presence of mRNA complementary to
shell precursor protein genes is underway. Since F hepatica
is auxotrophic for a remarkable number of compounds
including purines, pyrimidines, sterols, fatty acids, and a
10 number of amino acids (Kurelec 1972) we anticipate the
ability to successfully label macromolecules even in amni-
otic fluid of the avian egg. Successful isotopic labeling of
shell precursor proteins will enable a range of analyses
concerning shell crosslinking and shell architecture to be
15 performed.
Example 15
Analysis of Eggshell Cross-Links Using Solid State
20 Nuclear Magnetic Resonance NMR
Cross-links in insect cuticle have been successfully
probed employing solid state 13C and 15N NMR (Schaeffer,
et al, 1987). In this procedure tobacco hornworm larvae
25 were injected with either 13C (ring labeled) dopamine to
label catechols or with 15N histidine; NMR analysis of intact
cuticle revealed the presence of covalent linkages between
protein bound histidine and catecholamine dopamine. Simi-
lar analyses will be carried out in the trematode system
30 labeling worms with 13C tyrosine as DOPA precursor, 15N
lysine and 15N histidine to probe possible crosslinks
between vpB, rich in DOPA and lysine, and vpC, rich in
DOPA and histidine.
35 Example 16
Analysis of Eggshell Cross-Links Using Proteolysis
with Dopa Specific Enzymes
40 Another approach to characterize crosslinks would rely on
the use of Dopa-protein digesting proteases recently
described from the marine Alteromonas species (Dohmoto
and Miyachi 1991). These enzymes completely digested
byssyl thread and were found to contain at least two pro-
45 teases that preferentially cleaved the peptide bond next to
DOPA. For this study we propose to digest eggshells har-
vested and cleaned from the uteri of F. hepatica with a crude
Alteromonas protease (buffer O.1M Tris-ascorbate pH 7.5)
for as long as necessary to render the eggshells completely
50 soluble. When this has been accomplished, residual material
will be removed by centrifugation, and the supernatant
lyophilized, redissolved in 5% acetic acid and separated on
C-18 reversed phase HPLC. Fractions containing aromatics
will be examined by amino acid analysis, UV spectropho-
55 tometry and, if encouraging, by mass spectrometry.
Example 17
Analysis of Eggshell Cross-Links Using Specific
60 Labeling Through Nucleophilic Addition of 14C
Glycine Ethylester
The greatest limitation in working with quinone-tanned
proteins is that they typically resist every treatment short of
65 complete hydrolysis. For this reason entirely, it is expedient
to work with pretanned precursors. The present inventors
adopted a labeling protocol developed by Simon and Green
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(1988) for following the course of cross-linking in involu-
crin, a major protein of the epidermis. Like the vpB and vpC,
involucrin (mol. wt. 100 kDa) consists of a degenerate series
of repeating consensus decapeptides that are rich in gluta-
mine (Eckert and Green 1986). It was recently observed that
involucrin in terminally differentiated epidermal cells is
associated with tissue transglutaminase, a crosslinking
enzyme.
An iso-peptide bond is formed from peptidyl-glutamine
and -lysine. In undertaking to determine which glutamines
are targeted for cross-linking, Green and co-workers opted
for an approach that discarded the physical problems asso-
ciated with crosslinking (such as insolubility and intracta-
bility). This was done by overwhelming the natural amine
donor peptidyl lysine with 14C glycine ethylester. The 14C
glycine ethyl ester modified protein could be i) visualized on
gels, ii) isolated by HPLC and iii) digested into a family of
radioactive and nonradioactive peptides. These of course
can be easily purified and sequenced. In the case of invo-
lucrin, the results obtained were most intriguing and totally
unexpected. Of the 39 or so consensus repeats in intact
involucrin, glutamines in only two of the repeats were
consistently labeled (Simon and Green, 1988).
VpB and vpC are more degenerate in terms of repeats but
they can be analogously treated with mushroom tyrosinase
at pH 8.0 (phosphate buffered saline) to form messy cross-
linked aggregates of high molecular weight (Waite and
Rice-Ficht, 1987). Lysines are implicated in the cross-
linking by two lines of evidence including i) lysine levels
decrease with DOPA as the course of the oxidation proceeds,
and ii) vpB is less trypsin-labile following oxidation (Waite
and Rice-Ficht 1987; unpublished observation). If lysine in
vpB were overwhelmed with 14C glycine ethyl ester (10 uCi,
2 mM), then in principle this protein (200 ug/50 ul) too
should become increasingly labeled without necessarily
becoming insoluble or resistant to trypsin. A cautionary note
is advisable since other cross-links are possible. Even so, if
crosslinking is limited the vpB would be digested with
trypsin and tryptic peptides could be screened via C-8
reversed phase HPLC (Waite et al 1985) and liquid scintil-
lation for `hot' peaks. Characterization of hot peaks by
amino acid analysis and microsequencing will help identify
the position and number of dopaquinones targeted. There are
at least four potential addition sites for glycine ethylester in
peptidyl-dehydrodopaquinone.
Two additional catecholoxidases may be used in these
studies: one will be extracted from the fresh byssal threads
of the mussel (Geukensia demissa) in the following manner
Byssal threads (1-23 g) are macerated then triturated by
hand in a ground glass tissue grinder with two volumes of
1M NaCl, 0.05 M Tris pH 7.5, and 0.001% Triton X-100
(Waite 1985). Insolubles are removed by centrifugation
(5000xG, 30 min), and the material precipitating between
10-30% (w/v) ammonium sulfate is harvested by centrifu-
gation and redissolved in a small volume of high saline
buffer. Chromatography is performed consecutively on Frac-
togel 55S (elution buffer—IM NaCl, 0.05 M Tris pH 7.5),
Sephadex LH-60 (elution buffer-40% aqueous methanol)
and Sephadex G-75 (elution buffer 0.05 M Tris and 4M
urea). Enzyme is homogeneous by SDS Page and has a
specific activity of 2040 units (Rzepecki and Waite 1989).
Alternatively, the second enzyme may come from the vitel-
laria of Fasciola hepatica.
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Example 18
Radiolabeling of Shell Proteins to Identify New
Amino Acid Derivatives Resulting from Natural
5 Crosslinking
F hepatica may be labeled with radioactive isotopes
corresponding to putative nucleophiles in the shell cross-
linking process (cysteine, histidine and lysine) as well as
10 with labeled tyrosine and the shell protein precursors puri-
fied. Each of the proteins will be hydrolyzed under reducing
conditions as previously described for standard amino acid
analysis of DOPA proteins (Waite and Rice-Ficht 1987) or
reduced to amino acids enzymatically (Rice and Green
15 1977). New peaks on the HPLC profile will be compared
with standards eluting at those positions in order to identify
new species produced by crosslinking.
Example 19
20
Use of Bifunctional Crosslinking Agents in
Combination with Monospecific Antisera to Study
Protein-Protein Interactions in Shell Assembly
25 Worms will be labeled with radioisotopes to facilitate
analysis of small quantities of protein in the following
studies. The label of choice will be determined by the protein
which is to be analyzed. VpB is void of cysteine residues
although methionine would be suitable for labeling; vpC is
3o deficient in both sulfur containing amino acids and would be
suitably labeled with glycine or arginine.
After labeling in vitro, worms will be isolated and newly-
formed eggs of the distal uterus will be carefully extruded.
The newly formed eggs would contain minimal native
35 crosslinks as yet since they remain fully positive by staining
with Arnow's reagent and yet this is the earliest stage in
which one might expect to find the vitelline proteins in their
ultimate relative positions in the shell. These immature
shells may be: exposed to reversible crosslinking reagents,
40 shell protein precursors extracted (that are not as yet trapped
within the matrix), and the crosslinked species identified
with a monospecific antibody. The identity may be con-
firmed following dissolution of the crosslink and SDS PAGE
analysis.
45 Any choice of cross-linking reagent must be made with
solubility in mind and the ease of introduction of the
cross-linker into the immature shell structure; to a degree
this is empirical and a number of reagents may have to be
tested. An ideal cross-linking reagent for these studies
50 considering the composition of the proteins to be crosslinked
is the thiol cleavable bifunctional reagent DSP [dithiobis
(succinimidyl propionate)] . Since no cysteines are present in
vpB or vpC and the naturally occurring crosslinks are not
labile to reducing agents, the artificially induced crosslinks
55 will be distinguishable from the natural. This procedure has
been applied to the study of protein disulfide isomerase
binding to immunoglobulin (Roth and Pierce 1987) through
crosslinking the proteins in vivo, immunoprecipitation of
complexes with antibody directed against one protein of the
60 complex and analysis via SDS-PAGE (reducing gel). An
alternate approach using bis(imidoesters) has been applied
to the study of a higher order structure, the pyruvate dehy-
drogenase complex of Bacillus stearothermophilus (Pack-
man and Perham 1982). In analysis of these associations the
65 cleavage step (acetonitrile and methylamine) was introduced
between two dimensions of a diagonal gel electrophoresis;
proteins which migrate away from the diagonal were pre-
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viously cross-linked. Proteins may again be identified using
antibody. The goal of the project is to analyze the proximity
of the various vitelline proteins in the three-dimensional
structure and to better define the role of each in shell
architecture.
Example 20
Expression of Recombinant Eggshell Precursors in
Prokaryotic Expression Vectors
In order to obtain enough protein for study in a form
which is more soluble and manipulable, recombinant protein
representing vpA, vpB and vpC will be produced in E. coli.
The E. coli host does not carry enzymes to catalyze the
oxidation of tyrosine and the products will be unmodified.
The vector of choice for production of protein is the pGEX
vector which employs the glutathione-S-transferase gene of
Schistosoma as a purification tool (Smith and Johnson
1988). The recombinant protein will be produced as a fusion
with the GST and affinity purified on glutathione-agarose
beads. A proteolytic cleavage site has been introduced
between the GST and the foreign protein permitting release
with either factor X or thrombin. This permits a single step
purification of any of the vitelline proteins followed by the
release of the proteins from the GST carrier. The non-fused
protein can then be employed in the studies outlined below.
Example 21
Enzymatic Oxidation of Eggshell Precursors
An analysis of the purified vitelline protein precursors
reveals each of them to be post-translationally modified
(tyrosine to DOPA) to a different degree. vpC is most
heavily modified (100%); vpB is modified to a lesser extent
(60%) and vpA contains only 30% modified tyrosine.
Sequence analysis has shown that with rare exception a
given tyrosine residue is modified 100% with others com-
pletely unmodified (Waite and Rice-Ficht 1992). The basis
for this modification is uncertain since there appears to be no
absolute consensus sequence flanking the modified residues.
Recombinant protein will be enzymatically modified to
varying degrees in vitro (Waite and Rice-Ficht 1987) and
specific tryptic peptides analyzed for DOPA composition.
Example 22
Production of Polyvalent and Monoclonal Antibody
for Fine Structure Localization of Proteins Involved
in Shell Production
The production of antibody directed against specific vitel-
line proteins has in the past proved problematic; the prob-
lems are based on: i) an apparent lack of antigenicity of the
proteins; and ii) antibody raised against the proteins is often
directed to the DOPA moieties producing a cross-reacting
antisera. To manufacture reagents specific for each protein
we propose to inoculate rabbits (for polyspecific sera) and
mice (for monoclonal antibody) with denatured recombinant
protein representing each of the vitelline proteins in RIBI's
adjuvant. The rationale is to raise antibody against the
primary sequence of the proteins which will be useful in
distinguishing proteins in Western blot or fixed, embedded
tissue (i.e. in a denatured state). High titer sera directed
specifically against vpB and one monoclonal antibody spe-
cific to vpB have been generated; in order to probe different
30
epitopes of vpB, vpC or vpA, additional reagents may be
required. Shell precursors and enzymes in the vitelline
globules may be visualized through transmission EM and
immunogold tagging. The localization of each protein to
5 each phase of the vitelline globule is critical to the under-
standing of how emulsions of the proteins are formed and
later combined prior to quinone tanning.
Example 23
10
Coacervation Produced Capsules Containing vpB
Capsules composed of vpB ranging from 5 to 200 microns
in size were produced through coacervation technology as
15 
follows: 200 µl of phosphate buffered saline solution, pH
7.2, containing 2 mg recombinant vpB and 2 mg recombi-
nant proline-rich protein from F hepatica was vortexed; 240
µl of 2-isopropanol (coacervating agent) was added drop-
20 wise while vortexing. As mixing continued, 60 ml of sodium
sulfate solution (30% by weight sodium sulfate in dH2O)
was added dropwise. Fixation was achieved by addition of
54µl of formaldehyde solution (37% in dH2O) while mixing
for 10 minutes.
25
Example 24
Protein Microspheres Produced Through Oil in
Water Emulsion Technology
30
Encapsulation and release of small molecules, entrapment
of tritiated glycine. Protein mcrospheres were produced
using the following formulation: Microspheres were pro-
duced as a composite between bovine serum albumin (Frac-
35 tion V, Sigma Chemicals) and recombinant vpB. 100 ml of
olive oil is stirred for 30 minutes in a 400 ml beaker using
a Caframo ultra high torque stirrer at a speed at 1200 rpm
(300-1800 rpm) specific for the size of capsule to be
produced. Then 2 ml of a 126 mg/ml protein solution
40 containing bovine serum albumin (125 mg) and vpB (1 mg)
and a compound to be dispersed (1.25 mg glycine; 30
microcuries [3H] glycine) was added to the oil and the
stirring continued for 30 minutes at 1200 rpm. Aqueous
droplets of protein in the emulsion were crosslinked through
45 the addition of 50 microliters of 37% formaldehyde (or
glutaraldehyde 0.1-25%) followed by stirring for an addi-
tional 15-30 minutes. Glycine, a capping agent for aldehyde
groups, was then added (125 mg/ml, 50 microliters of a 125
mg/ml solution in phosphate buffered saline) and the emul-
50 sion stirred for an additional 15 minutes. Microspheres were
then collected through centrifugation (10 minutes, 2400
rpm, Beckman TH-4 centrifuge) and the mcrospheres
washed in ether (twice in 20 ml diethyl ether) to remove
residual oil. Size is determined by oil viscosity, stirring
55 speed and surface properties of the encapsulant.
Release of [3H] glycine was determined by rocking the
microcarriers in a solution of phosphate buffered saline
(PBS) or in PBS:bovine serum (50:1). Samples were taken
throughout a 72 hour period and analyzed through liquid
60 scintillation (P. Baukudumbi, K. H. Carson, A. C. Rice-Ficht
and M. J. Andrews, on the diameter and size distribution of
bovine serum albumin (BSA) mcrospheres, Journal of
Microencapsulation (2004)). As shown in FIG. 2, it was
found that using the present invention the release of a small
65 molecule, [3H] glycine, was delayed for up to eight hours
with 72-75% released by that time point. The remaining
25% was released over 72 hours.
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Example 26 antibody titers at substantially extended times when com-
pared to lower doses of botulinum neurotoxin A, fragment
VpB/Albumin Protein Microsphere Utility as a C.
Vaccine Delivery Vehicle for Extended or
Controlled Release of Tetanus Toxoid Fragment 5 Example 29
Microcarriers produced through the same emulsion for-
mulation as described for glycine entrapment were utilized
in the following studies. Groups of six mice were treated via
subcutaneous injection of encapsulated tetanus toxoid (TT;
10 micrograms per dose) manufactured with oil in water
emulsion technology (above). Composite capsules con-
tained the following: 74% albumin:26% vpB. A second
group of capsules were bovine serum albumin loaded with
TT (99.99% bovine serum albumin; 10 micrograms TT) and
composite (vpB/albumin) loaded with TT (10 micrograms/
dose).
The vpB microencapsulating additive was also used to
entrap tetanus toxoid for the above studies. Capsules were
introduced subcutaneously as a depot and serum antibody
titers monitored for a period of weeks using enzyme linked
immunosorbent assay_ELISA (FIG. 3). Use of 26% vpB in
the composite capsule formulation resulted in an extended
period of elevated serum antibody response to tetanus tox-
oid, at week 11 a level more than 10 fold that of TT loaded
albumin capsules was observed.
Example 27
VpB/albumin protein microsphere utility as a vaccine
delivery vehicle for botulinum toxin fragment. Microcarriers
produced through the same emulsion formulation as
described for glycine entrapment.
FIG. 4 is a graph that shows the results of botulinum toxin
encapsulated using the present invention and delivered as a
depot. Serum antibody titers for mice determined over a
period of 17 weeks are shown. Groups of 6 mice were
analyzed. Results are from pooled sera.
The hallmark of the composite capsule is the slow erosion
and the extended release profile (group 4C) when delivered
as a subcutaneous depot. Botulinum neurotoxin A (recom-
binant fragment C) was delivered as a subcutaneous depot
in: free form (5C, 2 micrograms per dose), and encapsulated
in protein (1C-4C). 4C is a 10 micron composite capsule
with 3% vpB; 97% bovine serum albumin; 2 micrograms
Bot toxin). Serum antibody response with this capsule
formulation is retained at 17 weeks. This is superior to the
delivery of the toxin in a free form which directs a high
serum antibody response at 5 weeks that diminishes sharply
at 7 weeks.
Example 28
Dose Dependence of the Serum Antibody Response
to Encapsulated Botulinum Toxin Fragment C
FIG. 5 is a graph that shows the immune response to doses
of botulinum neurotoxin A, fragment C trapped in the
composite capsule described above, were dose dependent.
The batches of capsules are identified by dose referring to
the mg dose of capsule. The capsule doses in milligrams
contain the following doses of hot tox: 0.2 mg-0.2 micro-
grams of toxin; 0.6 mg-0.6 micrograms of toxin; 2.0 mg-2.0
micrograms of toxin. Individual animals received 2 micro-
grams per dose. Results indicate that vpB albumin compos-
ite capsules carrying a 2.0 mg dose of capsule induce serum
Emulsion Capsules Used to Entrap Tetanous Toxoid
and Deliver Vaccine Through a Combination of
Subcutaneous/Oral Routes to Mice
10
FIG. 6 is a graph that shows the antibody response of six
mice injected subcutaneously with encapsulated TT com-
posite capsules. Capsules were produced through emulsion
technology described above entrapping tetanus toxoid (TT,
15 100 micrograms per dose). Groups of six mice were injected
subcutaneously with encapsulated TT composite capsules
(tetanous toxoid 10 micrograms per milligram of formula-
tion/bovine serum albumin 95%/recombinant vpB 5%, GI),
albumin/TT (bovine serum albumin 99.99%, tetanus toxoid
20 10 micrograms per milligram of formulation G2), empty
composite capsule (bovine serum albumin 95%/recombinant
vpB 5%, G3), tetanus toxoid unencapsulated, 100 micro-
grams (G4) and saline (G5). Dosing was performed as
follows: Groups 1-3 received: 10 mg of specified capsule
25 formulation (containing TT 100 micrograms) delivered sub-
cutaneously at time 0. Mice were boosted orally at weeks 3
and 6 with 10 mg of specified formulation in 250 microliters
of corn oil and buffer (1:1). Group 4 received 100 micro-
grams of unencapsulated TT at time 0 and was boosted at 3
30 and 6 weeks orally with 100 micrograms TT in 250 micro-
liters of corn oil:buffer (1:1). Group 5 received no treatment
Sera were pooled for analysis and serum antibody measured
through ELISA using tetanus toxoid as antigen. Secondary
antibody detected IgG. Results indicate that the composite
35 formulation which contains vpB at a level of 5% and tetanus
toxoid as antigen results in an extended presentation of
antigen to the immune system and a higher serum antibody
level (3 fold) at extended times when compared with a
control empty composite capsule (G3). Parallel studies with
40 doses of 200 micrograms of tetanus toxoid revealed similar
results.
FIG. 7 is a graph that shows cellular immune response as
measured by tritium uptake for the same groups as FIG. 6 at
21 weeks. Splenocyte blastogenesis from the same mice at
45 the conclusion of the studies indicated that a strong cell
mediated response had also been obtained when utilizing
vpB as an additive (group 1).
50
Example 30
Assay for the Adhesive Properties of Vitelline B
Protein
Vitelline B protein (4 mg) can be dissolved in 150 ml of
55 Phosphate Buffered Saline (PBS-10 mM phosphate, 120
mM NaCl, pH 7.4) or 150 ml of 5 M Guanidinium HCl. This
solution can be combined with an equal volume of 30%
hydrogen peroxide (25 ml of each). The solution can be
placed between the surfaces to be adhered to one another,
6o and placed in a 45° C. oven overnight in order to cure.
Other chemical oxidants can also be used including
chemicals, enzymes, such as mushroom tyrosinase, and
buffers with extreme pH to convert tyrosine in the vpB
recombinant protein to DOPA and DOPA quinone and
65 impart sticky properties to the protein. The use of a dena-
turant is optional, and others such as urea can be used in
place of guanidinium hydrochloride. General methods for
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making proteins adhesives are taught Hwang, D. S., Yoo, H.
7., Moon, W. K., and Cha, H. J. (2004) Applied and Environ.
Micro. 70, 3352-3359, relevant portions incorporated herein
by reference.
Example 31
Alginate-vpB Composite Capsules for Vaccination
with Live Brucella abortus
Capsule design 1: Bacteria 1x104-1x1010 were suspended
in 2 ml phosphate buffered saline and mixed with 10 ml of
a 1.5% alginate solution in a 60 ml syringe. The syringe was
attached to the inflow port of an Encapsulator device (Ino-
tech, Inc.) and delivered dropwise through a nozzle of
defined aperture (50-700 microns) into a CaC12 bath (10 mM
CaC12, 225 ml). Beads thus formed were incubated with
stirring for 5 minutes. CaC12 was withdrawn and a solution
of either 0.05% poly-L-lysine or 0.05% poly-L-lysine in
CaC12 was added along with 0.0625-1 mg of vpB protein.
This solution was stirred for 10 minutes and withdrawn. The
capsules were then washed once for 1 minute with 100 ml
MOPS buffer, then once for 5 minutes with 150 ml MOPS
buffer. The MOPS buffer was withdrawn and 100 ml of a
0.03% solution of alginate was added to the beads and
stirred for 5 minutes. Alginate was again withdrawn and the
capsules washed with 100 ml MOPS buffer for 1 minute,
drained and washed with an additional 150 ml MOPS buffer
for 5 minutes. Capsules were collected and stored in MOPS
buffer at 4° C.
Capsule design 2: Alternatively, the vpB protein, at the
same concentrations indicated in capsule 1, was included
with the alginate and bacteria along with the contents of the
syringe and dropped into the CaC12 solution. In this embodi-
ment the vpB was not included in the `shell', but as
component of the core. Both applications were tested in
mice.
FIG. 8 is a graph that shows the results obtained from red
deer vaccination studies conducted with capsule design 1
only using the following approach: Groups of 4 red deer
were vaccinated orally or subcutaneously with alginate or
alginate composite capsules containing entrapped live Bru-
cella abortus vaccine. Animals were bled prior to com-
mencement of the study for baseline serum titers Animals
were vaccinated on day 1 and boosted with the same dose
and formulation at 4 weeks. Animals were challenged with
the vaccine strain on week 7 and sacrificed at week 14. The
vaccination groups are as follows: empty composite cap-
sules (subcutaneous), unencapsulated vaccine strain S19
(injected), alginate encapsulated vaccine strain (injected),
composite encapsulated vaccine strain (injected), encapsu-
lated vaccine strain (oral), composite encapsulated vaccine
strain (oral). Each animal received a dose of 7x109-1x1010
organisms per dose. The results of this study are indicated
below.
Serum IgG titers of red deer at week 11 indicate that
encapsulated forms of delivery out perform the unencapsu-
lated vaccine with respect to maintenance of serum antibody
titer. At 11 weeks the titer of animals vaccinated with
composite capsules was lower than that of alginate alone
while the orally dosed animals showed higher titers with
composite capsules that those encapsulated with alginate
alone.
FIG. 9 is a graph that shows the kinetics of the induction
of Immoral immunity as a result of subcutaneous vaccina-
tion. Although the titers of animals receiving unencapsulated
S19 are falling at 7 weeks, that of both encapsulated forms
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is rising. The alginate encapsulated vaccine is producing a
steep increase in titer at 4 and 7 weeks. The composite
alginate/vpB encapsulated vaccine is rising at a slower rate
providing a lower level, longer term release of the vaccine.
5 Therefore, longer term release was made possible by the
inclusion of the vpB protein additive of the present inven-
tion, possibly due to its slow decomposition enhancing the
performance of capsules in extended release.
10 Example 32
Alginate-vpB Composite Capsules for Vaccination
with Live Brucella melitensis in Mice
15 To determine the utility of vpB in composite capsules the
present inventors used capsule design 1 and 2 in the delivery
of an attenuated Brucella melitensis strain to mice. All
animals except group 1 received an innoculum of 1x105
organisms through intraperitoneal injection at the initiation
20 of the study. Serum antibody titers have been monitored
weekly over a three week period following vaccination. The
groups as summarized in Table 2. The results are shown in
FIG. 10. Improved antibody titers against the live vaccine
strain are seen with the use of capsule formulation #2, in
25 which vpB is included with the alginate core and with the
vaccine strain. It is predicted that vpB containing formula-
tion will experience extended serum antibody titers and
enhanced protection over other methods. Alginate capsules,
which do not contain any vpB additive, failed to produce
30 antibody titers as elevated as those of vpB containing
alginate capsules.
TABLE 2
35 Intraperitoneal Injection of Brucella melitensis in mice
Number of
Group Organisms animals per
INOCULUM # Dose per dose group
MOPS buffer 1 0.1 ml 105 10
40 Alginate 2 0.1 ml 105 10
Alginate/Brucella 3 0.1 ml 105 10
mellitensis(2*)
Alginate/vpB 4 0.1 ml 105 10
capsule 1/
Brucella
45 melitensis(1*)
Alginate/vpB 5 0.1 ml 105 10
capsule 2/
Brucella
melitensis(3 *)
Brucella 6 0.1 ml 105 10
50 melitensis
unencapsulated
Example 33
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Alginate-vpB Capsules for Controlled Release of
an Active Protein, Interferon tau
Capsule design 1 was used as follows. Interferon tau
60 (from Dr. Fuller Baser, Dept Animal Science, TAMU) 1 ml
(10$ units) was suspended in 1 ml MOPS buffer and mixed
with 5 ml of a 1.5% alginate solution in a 60 ml syringe. The
syringe was attached to the inflow port of an Encapsulator
device (Inotech, Inc.) and delivered dropwise through a
65 nozzle of defined aperture (50-700 microns) into a 10 mM
CaC12 bath (225 ml). Beads thus formed were incubated with
stirring for 5 minutes. CaC12 was withdrawn and a solution
US 9,555,073 B2
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of either 0.05% poly-L-lysine or 0.05% poly-L-lysine in
CaCl2 was added in combination with 0.0625-1 mg of vpB
protein. This solution was stirred for 10 minutes and with-
drawn. The capsules were then washed once for 1 minute
with 100 ml MOPS buffer, then once for 5 minutes with 150
ml MOPS buffer. The MOPS buffer was withdrawn and 100
ml of a 0.03% solution of alginate was added to the beads
and stirred for 5 minutes. Alginate was again withdrawn and
the capsules washed with 100 ml MOPS buffer for 1 minute,
drained and washed with an additional 150 ml MOPS buffer
for 5 minutes. Capsules were collected and stored in MOPS
buffer at 4° C.
Encapsulated interferon tau was delivered to mice as a
treatment regimen for virally induced neurodegenerative
disease. Capsules of 400 microns in diameter containing a
dose of 2x106 units were delivered through intraperitoneal
injection.
SJL mice were infected with 5x104 pfu BeAn strain of
Theiler's virus or mock infected with PBS. The mice were
assigned to one of the following groups (10 mice per group)
described in Table 3 below. The dose IFN will be 105 units
i.p. which has been shown to be effective in the treatment of
TVID as summarized in Table 3.
TABLE 3
Results from Study Groups
Group Infection Treatment
Route of
Treatment
Timing of
Treatment
A + IFN-T i.p Daily
B + IFN-T oral Daily
C + Saline i.p Daily
D + IFN-T i.p. Twice weekly
E + IFN-T oral Twice weekly
F + Saline i.p. Twice weekly
G + Saline oral Twice weekly
H — IFN-T i.p. Daily
I — IFN-T oral Daily
J + Encapsulated i.p. Once biweekly
IFNt
The mice have been weighed and evaluated for clinical
signs of disease at weekly intervals. Mice treated with
encapsulated INFt shown clinical improvement comparable
to that of mice receiving daily intraperitoneal doses. The
delivery of a dose of encapsulated INFt serves to reduce the
treatment regimen from once daily to once every 2 weeks.
Controlled release of a model protein, green fluorescent
protein, from capsules of type one design have been carried
out by loading of capsules during manufacture and monitor
of release kinetics over a two week period. Results indicate
release of only 5-6% of the protein within twenty four (24)
hours and sustained release of the protein over a 10 day
period from capsules of type one design. FIG. 11 shows the
fluorescence profile of the gfp released over a one week
period as determined through SDS polyacrylamide gel elec-
trophoresis and fluorescence analysis. Lane 1 illustrates gfp
released from an alginate capsule type 1 in 3 hours, lane 2,
24 hours and lane 3, 7 days. Release in a 24 hour period is
approximately 5-6% of the total encapsulated protein. The
gfp protein is the approximate molecular weight of inter-
feron tau and illustrates the predicted release profile of a
similar protein from this type of capsule.
It will be understood that particular embodiments
described herein are shown by way of illustration and not as
limitations of the invention. The principal features of this
invention can be employed in various embodiments without
departing from the scope of the invention. Those skilled in
k1,
the art will recognize, or be able to ascertain using no more
than routine experimentation, numerous equivalents to the
specific procedures described herein. Such equivalents are
considered to be within the scope of this invention and are
5 covered by the claims. All publications and patent applica-
tions mentioned in the specification are indicative of the
level of skill of those skilled in the art to which this invention
pertains. All publications and patent applications are herein
incorporated by reference to the same extent as if each
10 individual publication or patent application was specifically
and individually indicated to be incorporated by reference.
All of the compositions and/or methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
15 compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the compositions and/or methods and in the steps
or in the sequence of steps of the method described herein
20 without departing from the concept, spirit and scope of the
invention. More specifically, it will be apparent that certain
agents which are both chemically and physiologically
related may be substituted for the agents described herein
while the same or similar results would be achieved. All
25 such similar substitutes and modifications apparent to those
skilled in the art are deemed to be within the spirit, scope and
concept of the invention as defined by the appended claims.
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<210> SEQ ID NO 1
<211> LENGTH: 252
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide
<400> SEQUENCE: 1
Met Lys Met Lys Phe Thr Leu Val Leu Leu Leu Ala Ile Val Pro Leu
1 5 10 15
Thr Leu Ala Arg His Pro His Gly Lys Phe Asn Arg His Ala Ser Tyr
20 25 30
Asp Asp Arg Phe Lys His Arg Gly Tyr Arg Lys Glu Asn Asp Leu Asn
35 40 45
Asp Leu Lys Gly Lys Phe Ala Gly Arg Gly Lys Ala Leu His Gly Ser
50 55 60
39
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-continued
Phe Asp Lys Tyr Gly Asn Glu Asn Glu Arg Gly Arg Tyr Asp Asp Gin
65 70 75 80
Gly Lys Tyr Leu Leu Ala Gly Lys Ser Ala His Asp Gly Lys Tyr Gly
85 90 95
Met Tyr Gly Asn Met Tyr Ala Lys Gly Asp Phe Lys Ala Tyr Gly Asn
100 105 110
Glu Asp Glu Gly Ala Lys Phe Glu Glu Val Thr Thr Phe Arg Arg Gly
115 120 125
Gly Gly Asp Ser Gly Lys Lys Lys Ser Asp Asp Asp Thr Lys Gly His
130 135 140
Leu Lys Lys Phe Ala Asn Lys Gly Arg Gin Ser Lys Phe Asp Met Gly
145 150 155 160
Asn Val Lys Ala Asp Gly Gin Ala Ile Ser Asn Gly Asn Met Asn Ala
165 170 175
Gly Met Phe Asp Ser Gly Lys Asp Gin Gly Lys Met Asn Asp Gin Gly
180 185 190
Lys Glu Glu Ala Gly Lys Tyr Asn Ala His Gly Asn Leu Asp Leu Tyr
195 200 205
Gly His Leu Arg Gly Gly Gly Ser Ser Ala Ala Ser Lys Ser Glu Asn
210 215 220
Tyr Gly Asn Ala Arg Glu Ser Gly Arg Glu Pro Gly Arg Tyr Glu Lys
225 230 235 240
Glu Asp Asp Ala Arg Glu Thr Pro Tyr Asp Lys Ser
245 250
<210> SEQ ID NO 2
<211> LENGTH: 253
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide
<400> SEQUENCE: 2
Met Lys Met Lys Phe Thr Leu Val Leu Leu Leu Ala Ile Val Pro Leu
1 5 10 15
Thr Leu Ala Arg His Pro His Gly Lys Phe Asn Arg His Ala Ser Tyr
20 25 30
Asp Asp Arg Phe Lys His Arg Gly Tyr Arg Lys Glu Asn Asp Leu Asn
35 40 45
Asp Leu Lys Gly Lys Phe Ala Gly His Gly Lys Ala Leu His Gly Ser
50 55 60
Phe Asp Lys Tyr Gly Asn Glu Asn Glu Arg Gly Arg Tyr Asp His Arg
65 70 75 80
Gly His His Ser Leu Ala Val Lys Ser Ala His Asp Gly Lys Tyr Asp
85 90 95
Met Tyr Gly Arg Met Tyr Ala Lys Ala Asn Phe Asp Ala His Gly His
100 105 110
Glu Lys Glu Gly Thr Lys Phe Glu Glu Val Thr Lys Phe Arg Arg Gly
115 120 125
Gly Gly Gly Gly Gly Lys Lys Lys Ser Asp Asp Asp Thr Lys Gly His
130 135 140
Met Lys Arg Phe Ala Asp Lys Gly Met Lys Ser Lys Phe Asp Leu Gly
145 150 155 160
Asn Val Glu Ala Lys Gly Lys Ala Asp Ala Asn Gly Lys Met Gly Ala
165 170 175
►ni
41
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-continued
Leu Gly Lys Phe Asp Ser Gly Lys Asp Gln Gly Lys Met Asn Asp Gln
180 185 190
Gly Lys Glu Glu Ala Gly Lys Tyr Asn Ala His Gly Asn Leu Asp Leu
195 200 205
Tyr Gly His Leu Arg Gly Gly Gly Ser Ser Ala Ala Ser Lys Ser Glu
210 215 220
Asn Tyr Gly Asn Ala Arg Glu Ser Gly Arg Glu Pro Gly Arg Tyr Glu
225 230 235 240
Lys Glu Asp Asp Ala Arg Glu Thr Pro Tyr Asp Lys Ser
245 250
What is claimed is:
1. A method of making an extended release formulation
comprising:
providing a recombinant scrambled vitelline protein B
(vpB) peptide which retains the same amino acid ratio
as the ratio of amino acids 82-187 of the amino acid
sequence selected from the group consisting of SEQ ID
NO:1 and SEQ ID NO:2;
combining the recombinant scrambled peptide, one or
more active agents, a crosslinking agent and an alg-
inate; and
crosslinking the recombinant scrambled peptide, the one
or more active agents, the crosslinking agent and the
alginate to form the extended release formulation.
2. The method of claim 1, wherein the one or more active
agents are released for between about 1 hour to about 8
hours, or between about 1 hour to about 2 weeks, or between
about 1 hour to about 6 months.
3. The method of claim 1, wherein the one or more active
agents comprise a pharmaceutical agent, an enzyme, a
cytokine, a growth promoting agent, an antibody, an antigen,
a vaccine, a cell, a live-attenuated pathogen, a heat-killed
pathogen, a virus, a bacteria, a fungi, a peptide, a protein, a
carbohydrate, a nucleic acid, a lipid, mixtures and combi-
nations thereof.
4. The method of claim 1, wherein the one or more active
agents, and the alginate are combined with the cross-linking
agent and the peptide by coacervation, spray freezing,
extrusion, nebulization, spray drying or into liposomes.
DA
5. The method of claim 1, wherein the crosslinking agent
is poly-L Lysine and the ratio of the poly-L lysine to the
peptide is between 30:70 to 70:30 weight to weight.
20 6. The method of claim 1, wherein the crosslinking agent
is poly-L Lysine and the ratio of the poly-L lysine to the
peptide is between about 50:50 weight to weight.
7. The method of claim 1, wherein the crosslinking agent
is a cation or a polycation.
25 8. The method of claim 1, wherein the one or more active
agents is an antigen and the antigen comprises Brucella sp.
9. The method of claim 1, wherein the method further
comprises the step of lyophilizing the composition.
10. A method of making an extended release formulation
30 comprising:
providing a recombinant scrambled vitelline protein B
(vpB) peptide which retains the same amino acid ratio
as the ratio of amino acids in a central 33% portion of
the amino acid sequence selected from the group con-
35 sisting of SEQ ID NO:1 and SEQ ID NO:2;
combining the recombinant scrambled peptide, a poly-
Lysine crosslinking agent, one or more active agents
and an alginate to form a release formulation, wherein
the ratio of the peptide to the poly-Lysine crosslinking
agent is between 30:70 to 70:30 weight to weight; and
40 crosslinking the recombinant scrambled peptide, the poly-
Lysine crosslinking agent, the one or more active
agents and the alginate to form the extended release
formulation.
11. The method of claim 10, wherein the crosslinking
45 agent is poly-L Lysine.
